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ABSTRACT
   
   
            
        
  
FEBRUARY 2014
IDALIA ARACELY RODRIGUEZ, B.A., VIRGINIA COMMONWEALTH
UNIVERSITY
M.A., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Laurie R. Godfrey and Professor Raymond M.
Welsh

The divergence of the two superfamilies belonging to the Infraorder Catarrhini –
Cercopithecoidea (Old World monkeys) and Hominoidea (apes, including
humans) – is generally assumed to have occurred during the Oligocene, between
38 and 20 million years ago. Genetic studies indicate that this time period was
one of active genetic evolution under strong purifying selection for catarrhine
primates. This includes selective pressures on the glycoprotein
galactosyltransferase 1 (GGTA1) gene and subsequent inactivation “clocked” at
approximately 28 ma, possibly prior to the Cercopithecoidea/Hominoidea split.
The GGTA1 gene codes for an α1,3 galactosyltransferase (GT) enzyme that
synthesizes a terminal disaccharide, αgalactosyl (αGal), found on glycoproteins
and glycolipids on the surface of cells in the tissues of most mammals. Currently,
catarrhines are the only mammals studied for the terminal αGal residue that do not
express this sugar on their cell surfaces. The proposed selective advantage of this
mutation for catarrhines is the ability to produce anti-Gal antibodies, which may





be an effective immune component in neutralizing αGal-expressing pathogens, as
certain helminthes, many bacteria, including those found in primate guts, and
some viruses derived from GGTA1 positive species express αGal on their
surfaces. However, many viruses are known to utilize host cell carbohydrates in
various ways such as binding receptors or attachment proteins, making these
moieties “hot spots” for selective evolution. Cell surface αGal may have
predisposed ancestral catarrhines to pathogens and toxins that could utilize the
terminal sugar moieties on host cells as binding sites or in other capacities during
infection. I found that, in fact, the presence or absence of cell surface αGal
affects the course of certain viral infections. Infections of paired cell lines with
differential expression of GT showed that Sindbis viruses (SINV) preferentially
replicate in αGal-positive cells, whereas herpes simplex viruses type 1 and type 2
(HSV-1 and HSV-2) preferentially grow in cells lacking αGal. In both cases,
differences in infection levels resulted from the ability of the virus to successfully
initiate infection. This points to a role for αGal in the early stages of viral
infections. I also showed that GT knockout mice infected with HSV-2 had higher
viral load and greater pathology compared to WT B6 mice that naturally express
αGal. The increased susceptibility of KO mice to HSV-2 was not due to an
immune component as differences in viral load and pathology were even more
evident in immunocompromised mice. This clearly indicates that αGal expression
in cells or animal hosts can affect the course of viral infections. I was not able to
further confirm differences in susceptibility to HSV 1 and 2 using mouse
backcrosses (KO x WT). Unknown genetic factors, that are independent of αGal





expression, may be introduced during the crosses that need to be further
investigated. Infections of KO and WT mice with other herpes viruses did not
yield definitive data and require further studies with suitable reagents. The
mechanism by which GT-dependent differential susceptibility to viruses operates
still remains to be deciphered. However, it is clear that susceptibility to certain
viral infections is tied to the presence or absence of αGal on the surface of host
cells. Overall, these results have implications for the evolution of resistance to
viral infections in catarrhines. Pathogens exert great selective pressure on their
hosts, and it is possible that a pathogen, able to exploit αGal, could have helped
shape primate lineage evolution during the Oligocene.
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CHAPTER 1
INTRODUCTION

1.1 Catarrhine evolution and the glycoprotein, glycosyltransferase gene 1
(GGTA1) locus
The phylogenetic split of the two superfamilies belonging to the infraorder
Catarrhini – Cercopithecoidea (Old World monkeys; OWM) and Hominoidea
(apes, including humans) – occurred during the Oligocene, estimated at about 29
Ma (Steiper et al., 2004; Chatterjee et al., 2009; Zalmout et al., 2010). More
conservative estimates, primarily based on fossil evidence, place the OWM and
ape divergence sometime between 38-20 Ma, essentially bracketing the entire
Oligocene (Raaum et al., 2005; Stewart and Disotell, 1998; Steiper and Young,
2008; Perelman et al., 2011; Pozzi et al., 2011). Molecular studies indicate that
the early part of the Oligocene epoch (~35.0-23.0 Ma) was a period of active
genetic evolution under strong purifying selection for catarrhines (Galili et al.,
1991; Koike et al., 2007). This may have included a mutation on the glycoprotein
galactosyltransferase 1 (GGTA1) locus. Catarrhini are unique among mammals
because a loss-of function mutation, which has been molecularly clocked at
approximately 28.1 million years ago, resulted in the inactivation of the GGTA1
gene (Figure 1) (Koike et al., 2007). In animals with an active GGTA1, the gene
codes for the α1,3 galactosyltransferase (α1,3GT or GT) enzyme, which is
responsible for the addition of the terminal galactosyl unit to αGal
(Galα1,3Galβ1,4GlcNAc-R) carbohydrate chains found on cell surface





glycoproteins and glycolipids in the tissues of most mammals (Galili et al., 1985;
Galili et al., 1987; Galili et al., 1988). Due to loss of GT expression, OWM and
apes do not express the cell surface carbohydrate, αGal (Galili and Swanson,
1991; Koike et al., 2002). All other extant primates – Platyrrhini (New World
monkeys (NWM)) and Strepsirrhini (lemurs and lorises) (Galili et al., 1988; Galili
and Swanson, 1991) — retain an actively expressed α1,3GT gene and therefore
have enzymatic activity that catalyzes production of the terminal galactose sugar.

Figure 1: Primate phylogeny on the geological time scale. The Hominoidea and
Cercopithecoidea lineages diverged during the Oligocene, some time after 28.1 Ma
when the GGTA1 gene was inactivated. The shaded area highlights the primate
lineages lacking αGal expression.



The significance of GGTA1 inactivation is of interest to studies in primate
evolution for several reasons: (1) inactivation occurred during the Oligocene
epoch, a period of ambiguity in catarrhine evolutionary history; (2) inactivation
occurred in relatively few taxa in the Order Primates, but active expression is
conserved across the vast majority of Class Mammalia, and of most importance
for this dissertation; (3) suppression of αGal expression in catarrhines has been
associated with a selective advantage against pathogenic agents.

1.2 Primate biogeography and biodiversity at the Eocene-Oligocene
transition
The Grande Coupure at the Eocene-Oligocene boundary is characterized by a
shift in global climate commonly referred to as “greenhouse to icehouse”
(Prothero 1994; Seiffert, 2007; Pearson et al., 2008; Maravelis and Zelilidis
2012). Cool conditions and pronounced seasonality continued for most of the
epoch until the onset of warmer climate approximately 25 Ma. The transition
from the late Eocene into the late Oligocene is also marked by a massive turnover
of marine biota as well as terrestrial fauna and flora (Prothero 1994; Kappelman
et al., 2003; Pearson et al., 2008; Figueirido et al., 2012; Maravelis and Zelilidis
2012; Wade et al., 2012). Terrestrial faunal biogeography and diversity during
the Oligocene epoch were likely influenced by geographic and climatic changes
such as fluctuating Antarctic ice sheet formation, increased aridification and
seasonality and a significant drop in global temperature and sea levels (Seiffert
2007; Maravelis and Zelilidis 2012; Wade et al., 2012). Additionally, the fall in





sea levels opened routes between previously unconnected land masses and
permitted migration (Kappelman et al., 2003; Figueirido et al., 2012; Maravelis
and Zelilidis 2012) that may have, in turn, affected faunal extinctions during the
late Eocene, and faunal diversity into the late Oligocene (Kappelman et al., 2003;
Figueirido et al., 2012).

Prior to the Eocene-Oligocene boundary, primates were widely distributed in
Africa, the Arabian Peninsula, Asia and even the mid-latitudes of North America
and Europe (Seiffert, 2007; Williams et al., 2010). In the latter part of the
Oligocene, primates in North America disappeared, as did many stem
strepsirrhine and haplorrhine lineages in Africa and Afro-Arabia (Seiffert, 2007).
Cool temperatures and habitat fragmentation in northern latitudes may have
restricted primate latitudinal distribution, while equatorial Africa, despite
experiencing decreased plant species diversity and cooler temperatures, retained
widespread tropical forest habitats suitable for primates (Seiffert, 2007).
Paleontological evidence shows stem anthropoids or catarrhines (i.e., the
Oligopithecidae, Parapithecoidea, Propliopithecidae) at localities in Africa, AfroArabia and Asia during the early Oligocene (Williams et al., 2010; Ducrocq et al.,
2011) although many of these lineages were extinct by the early Miocene (Seiffert
2007). Fossil remains of stem catarrhines such as Aegyptopithecus derive from as
late as 29-30 Ma, but a scarce paleontological record from the mid-Oligocene
makes discerning phylogenetic relationships or divergence dates between such





stem taxa and crown catarrhines from the Oligocene-Miocene boundary very
difficult (Seiffert, 2007; Zalmout et al., 2010). Even the most informative
sediments—such as those of the Fayum depression in Egypt—lack many primate
remains (Steiper et al., 2004; Zalmout et al., 2010), resulting in a chronological
gap in the primate paleontological record.

The timing of the GGTA1 mutation can inform on the maximum bound for the
phylogenetic split of catarrhines. The mutation occurred in a basal catarrhine
prior to the divergence of cercopithecoids and hominoids. Therefore, the
phylogenetic split of these two groups must have occurred sometime after 28.1
Ma. It should be noted, however, that the timing does not indicate an exact
divergence time for the catarrhine lineages or set a minimum bound for the split.
The last common ancestor of OWMs and apes carrying the ΔGGTA1 gene may
have survived for a long period of time after the mutation was introduced into the
catarrhine lineage but prior to the divergence of cercopithecoids and hominoids.

1.3 GGTA1 function in class Mammalia
Loss of GT expression in catarrhines resulted in significant alteration to the
surface carbohydrate biology of these primates, but neither the physiological
function of αGal nor the metabolic consequences of inactivation of this locus in
animals with a functional GT gene is currently known. In non-catarrhine
primates, the function of GGTA1 appears to be under strong physiological
constraint, and the gene sequence has been highly conserved over evolutionary





time (Koike et al., 2007). Koike et al., (2007) suggest that inactivation of GGTA1
gene may have been detrimental to individuals and that loss of GT gene function
may have been possible only after its enzymatic role had been replaced, although
they do not conjecture on what replaced the enzymatic function in catarrhines.
The successful generation of experimental homozygous knockout (KO) pigs
(Nottle et al., 2007) and KO mice (Thall et al., 1995) demonstrate that loss of
GGTA1 activity is not lethal to an organism. A few abnormal health conditions
have been observed, including early-onset cataracts in some KO mice and
breeding problems in certain KO pig lineages (Koike et al., 2007). However,
breeding of other KO pig lineages and KO mice (Tanemura et al., 2000) resulted
in normal-sized litters that do not experience greater mortality or health defects
than wild type counterparts. This suggests that basal catarrhines could have
experienced loss of GT function without an elevated risk of morbidity or
mortality. Alternately, the loss of αGal from tissue surfaces may have served a
protective role during the evolution of catarrhines, and the benefits of losing gene
function may have outweighed any negative effects.

1.4 GGTA1 and infectious disease
Infectious agents can be powerful drivers of evolutionary change. Pathogens
exert great selective pressures on susceptible populations and can even be the
cause of extirpation or extinction (Pederson et al., 2007; Wyatt et al., 2008). An
example of the latter includes the species-level extinction of Rattus macleari after
the introduction of a parasite, possibly Trypanosoma lewisi, to Christmas Island in





the Indian Ocean (Wyatt et al., 2008). The large rat population, which was
immunologically naïve to the trypanosome parasite, was wiped out over a period
of less than 20 years (Wyatt et al, 2008). Infectious agents can also decimate
populations of susceptible hosts and have devastating consequences for these
populations. Ebola virus, with up to 95% mortality rates, have reduced Gorilla
and Pan populations in Africa over the past few decades (Leroy et al., 2004;
Bermejo et al., 2006). In regions of the Congo, outbreaks of Ebola have resulted
in Pan troglodytes population declines of up to 83% (Bermejo et al., 2006). This
can lead to regional extirpation or bottlenecks in the population. Occasionally
individuals survive due to genetic resistance (previous mutations carried in their
genome) or because new mutations have rendered them less susceptible than their
counterparts. This can be of adaptive significance to the entire species.

One of the most studied examples of genetic resistance in the human population is
the mutation CCR5- Δ32 on the leukocyte chemokine (C-C motif) receptor 5
(CCR5). The CCR5 gene locus was under selective pressure from pathogens
encountered by the human population centuries ago, namely the bacterium
Yersinia pestis and Variola virus (Hütter and Ganepola, 2011). The Δ32
mutation likely provided a level of resistance against these pathogens when they
were scourges in the human population, and today, individuals who possess this
mutation can also benefit due to their reduced risk of acquiring human
immunodeficiency virus (HIV) (Hütter and Ganepola, 2011).





It has been hypothesized that the GGTA1 gene locus has also been under
evolutionary selection due to pathogenic pressures (Galili et al., 1987; Galili et al.,
1988; Galili and Swanson, 1991; LaTemple and Galili, 1999). Catarrhine
primates that lack GT gene and αGal expression produce a natural antibody, antiGal, which recognizes the αGal disaccharide with high affinity (Galili et al., 1987)
and can induce phagocytic cell and complement activity (LaTemple and Galili,
1999; Rother and Galili, 1999). Production of natural antibodies that can
recognize and effectively neutralize pathogens may be beneficial for animal hosts
against a variety of parasites that express the αGal domain (Galili et al., 1984;
Galili et al., 1988; Avila et al., 1989; Hamadeh et al., 1992; Ramasamy and
Rajakaruna, 1997; Pingel et al., 1999). Fresh sera with functional complement
activity from different catarrhines can inactivate many different viruses that
express αGal (Welsh et al., 1975; Welsh et al., 1976; Welsh, 1977; Rother et al.,
1995; Takeuchi et al., 1997; Welsh et al., 1998; Kim et al., 2007). Sera from
other mammals, including New World monkeys, rabbits, rats, mice and guinea
pigs, do not lyse αGal-expressing viruses, as these species do not naturally make
anti-Gal (Rother et al., 1995; Welsh et al., 1975; Welsh et al., 1976). The ability
of anti-Gal to neutralize pathogenic agents via the complement system has been
heavily researched, and it is suggested that loss of αGT gene activity was favored
during catarrhine evolution because it allowed immune recognition of pathogens
expressing αGal (Galili et al., 1987; LaTemple and Galili, 1999; Rother and
Galili, 1999). As such, suppression of the GT gene would have been necessary to
develop the ability to produce anti-Gal and not also stimulate an autoimmune





response (Galili et al., 1987). Under this scenario, GT-deficient individuals
would have been indirectly protected from αGal-expressing pathogens by the antiGal activity.

1.5 Selection for ΔGGTA1 gene during catarrhine evolution
My alternative hypothesis is that positive selection for GT gene inactivation may
have been favored because loss of αGal residues directly altered host
susceptibility to infections. The proteins on cell surfaces are involved in
interactions with the surrounding environment, and the terminal carbohydrates
that decorate these proteins are prime candidates for pathogens, including viruses,
which can utilize carbohydrates as binding receptors or in other capacities
(Olofsson and Bergström, 2005). Historically, selective pressures from pathogens
have led to major biochemical changes in carbohydrate biology of primates (Chou
et al., 1998; Hayakawa et al., 2001; Gagneux et al., 2003; Varki and Varki, 2007).
It is known that αGal can serve as a binding receptor for pathogens, as toxin A,
produced by Clostridium difficile, binds to the αGal moiety on host cells and
causes cytotoxic effects in these cells (Krivan et al., 1986; Clark et al., 1987;
Teneberg et al., 1990; Phelps et al., 2003). Hamsters are highly vulnerable to
severe infections by C. difficile because they express high amounts of αGal on
intestinal epithelial cells, and these sites are specifically targeted by the bacterial
cytotoxin (Krivan et al., 1986). Experimental infections of rabbit and rat brush
border membranes and erythrocytes (Clark et al., 1987; Pothoulakis et al., 1991)
have showed that αGal-capped membranes are the binding sites for C. difficile in





these species, and greater expression was associated with more targeting by the
toxin (Krivan et al., 1986). Krivan et al. (1986), also found that human red blood
cells with the blood group B structure, Galα1,3Fucα1,2Galβ1,4GlcNac-R, would
bind toxin A after treatment with a fucosidase. The enzymatic removal of fucose
resulted in expression of Galα1,3Gal linkages on the cell membranes. Humans
can be infected with Clostridium spp. when intestinal or genital tract flora is
disturbed (Agrawal and Garg et al., 2012), but the binding receptor in humans has
not been determined. It is suggested that because humans do not naturally express
αGal, N-acetyllactosamine sites bearing molecular similarity to the Galα1,3Gal
structure serve as binding sites (Krivan et al., 1986; Teneberg et al., 1990).
As such, surface Gal residues are potential “hot spots” for selective evolution.

For basal catarrhines living during the Oligocene, GT expression may have
predisposed them to pathogenic agents able to exploit the GT pathway or its final
glycosylation product, αGal. Loss of GGTA1 activity and of surface αGal may
have increased resistance to such pathogens by GT-deficient catarrhines relative
to their GT-sufficient counterparts, resulting in selection for the ΔGGTA1 gene.
The pathogenic agents at work during the Oligocene epoch are unknown, and
therefore it is impossible to directly study the effects of such pathogens on
α1,3GT positive or negative hosts. However, we can conjecture about the role of
host GT activity during viral infections in the past by studying the interactions of





GT-deficient and GT-sufficient hosts with modern day viruses. Arguments can
then be made regarding the potential for viral infectivity (or host resistance) in the
presence or absence of GGTA1 gene activity.

My current hypothesis does not contradict the theory that anti-Gal production was
favored in the evolution of disease resistance for catarrhines. Instead, it attempts
to expand our understanding of the selection mechanism(s) that drove evolution
of the GGTA1 gene. In fact, the inactivation of the GGTA1 gene, coupled with
the production of anti-Gal, point to strong selective pressure for reduced
expression of the αGal epitope on the tissues of catarrhines. It is possible that GT
activity was lost due to neutral selection, through the accumulation of mutations
on the gene locus that had no benefit or detrimental effect on the host. This can
be easily verified, as active host expression of GGTA1 or αGal would have no
effect on the course of viral infections in that host. It is also possible that certain
viruses may preferentially infect hosts in the absence of GT expression. This may
not necessarily contradict my working hypothesis that GT activity facilitates the
course of a viral infection. Today, different viruses employ vastly different
strategies to establish infections in hosts, and viruses that may have once
specialized in exploiting the GT pathway may have modified their infection
strategies since 28.1 Ma.





In order to demonstrate the possible adaptive significance of ΔGGTA1 for basal
catarrhines, it is necessary to show that GT or αGal expression in hosts is
required—or in the least—can enhance the capacity of infection for viruses
relative to non-expressing hosts. This will establish that GT or αGal expression
may play a role in host susceptibility to viral infections. Additionally, it is
important to provide a possible mechanism by which viruses may utilize the GT
pathway or sugar. Viruses are known to utilize carbohydrate residues during
entry into the cell (adsorption, penetration), or subsequently, during exit (release);
as such, viruses may use surface αGal in this capacity. Until now, glycan-based
interactions of pathogens and αGal positive host-cells have received only limited
investigation. This aspect of the evolution of the α1,3GT gene – the
differential ability of pathogens to infect host cells through utilization of the
GT pathway or sites containing αGal – is the topic of this dissertation.

1.6 Summary and Chapter goals
The goal of this chapter was to provide an overview of the inactivation of the
GGTA1 gene in basal catarrhines and of primate evolution during the Oligocene.
Little is known about direct selective pressures underlying catarrhine evolution
during this epoch; the period of catarrhine lineage evolution and the hominoid and
cercopithecoid phylogenetic split. Changes in global ecology such as colder
temperatures and reduced habitats likely affected primate biogeography and
diversity during the late Eocene and into the Oligocene. We hypothesize that a
pathogen, perhaps a virus, may have also played a role in shaping catarrhine





lineage divergence during this epoch. Inactivation of the GGTA1 gene
(molecularly clocked at the midpoint of the Oligocene epoch, ~28.1 Ma) resulted
in a major change in carbohydrate biology for catarrhines, and possibly sites for
pathogens to exploit. The pressure from pathogens able to exploit the GT
pathway may have been an impetus for selection of GGTA1 gene inactivation.
Understanding the possible basis for selection of the mutated gene may inform us
about some of the processes that helped shape primate lineage divergence during
the Oligocene.

1.6.1 Chapter goals
Below is a brief description of the goals of each chapter of this dissertation.

1.6.2 Chapter 2: Biology of GGTA1, anti-Gal and terminal carbohydrates
In Chapter 2, I establish the evolutionary origins of GGTA1. I review the role of
anti-Gal as a protective factor in infectious diseases of primates. I also discuss the
importance of terminal carbohydrates in viral infections and provide several
examples of pathogen-driven modifications of carbohydrate loci during primate
evolution.





1.6.3 Chapter 3: Materials and methods
In vitro and in vivo methods were utilized in order to understand the details of
viral infections in GT positive and GT negative hosts. Cell lines derived from
mice were used for in vitro experiments and a mouse model was utilized for in
vivo work.

In Chapter 3, I describe the origins of the cell cultures and mouse lineages utilized
in these experiments, as well as the significance of using a mouse model to study
concepts in primate evolution. I also describe the varied experimental methods
utilized in this research.

1.6.4 Chapter 4: Differential host susceptibility to viruses, in vitro results
Various cell lines were used to establish differential susceptibility to viral
infections in the presence or absence of GT activity in the host cell. Preliminary
results regarding the role of GT activity in viral infections were established in
experiments using cultured cells lines because of the ease of manipulation.

In Chapter 4, I describe the results from experiments with various cell lines. I
present evidence for GT-dependent differential susceptibility to viral infections,
primarily with Sindbis viruses and herpes simplex viruses 1 and 2. I show that
differences in infections of GT-positive and GT-negative cell lines by the
different viruses are based on the ability of the viruses to initiate infection in the





host. Additionally, I show that αGal may play a role in the ability of viruses to
establish infection. I also discuss experiments that were not successful or resulted
in ambiguous data.

1.6.5 Chapter 5: Differential host susceptibility to viruses, in vivo results
Differences in susceptibility to viruses can be tested in vivo using a mouse model
to verify that in vitro findings can translate to the organismal level.
In Chapter 5, I discuss the results of in vivo experiments. I show that the same
patterns of differential infection observed in the cell lines are observed in
experimental mouse lines. Clear and significant differences in susceptibility to
infections are seen in GT deficient vs. GT sufficient mice with Sindbis virus
infections of young mice and with herpes simplex 2 infections of adult mice. I
also show the results of experiments that generated inconsistent or ambiguous
data.

1.6.6 Chapter 6: Summary and Conclusions
In Chapter 6, I examine the data and interpret findings from the previous chapters.
Overall, infections of paired cell lines with differential expression of α1,3GT
showed that certain viruses preferentially replicated in α1,3GT-positive cells,
whereas others preferentially grew in cells lacking α1,3GT. Viral growth and
spread correlated with the ability of the different viruses to successfully initiate
infection in the presence or absence of α1,3GT expression. Additionally,
differences in gross pathology, onset of disease symptoms and mortality are
correlated with the presence or absence of α1,3GT host mice. The current study





demonstrates that α1,3GT activity plays a role in the course of infections for
certain viruses. Furthermore, this study has implications for the evolution of
resistance to viral infections in primates.





CHAPTER 2
BACKGROUND ON GGTA1, ANTI-GAL, TERMINAL
CARBOHYDRATES AND VIRUSES

2.1 GGTA1 gene and αGal
The genetic sequences that code for the ABO glycosyltransferases are found on
the human homolog for the GGTA1 gene. These glycosyltransferases likely form
a family that arose as a result of gene duplications (Gastinel et al., 2001). αGal is
chemically similar to the ABO blood group antigens, and the transferases
responsible for their biosynthesis share similarities in their catalytic domains
(Gastinel et al., 2001). The α-galactosyltransferase enzyme is a golgi
transmembrane protein that catalyzes the transfer of a non-reducing galactose to
an N-acetyllactosamine acceptor via the following reaction: UDP-Gal +
Galβ1,3GlcNAc-RèGalα1,3Galβ1,4GlcNAc-R. This results in Galα1,3Gal
capped glycan chains. In most mammals, including mice, rats, cows, rabbits,
hamsters, pigs, dogs and non-catarrhine primates, αGal residues are found on the
surface of nucleated cells and erythrocytes (Galili, 1993). These residues cap the
terminal ends of membrane-bound glycosphingolipids and glycoproteins (Galili et
al, 1987) and in secreted N-glycosylated glycoproteins such as thyroglobulin,
fibrinogen and IgG (Thall and Galili, 1990). With the exception of sperm cells
(Thall et al., 1995), the carbohydrate is abundantly expressed on the surface, up to
106 molecules per cell (Galili, 1993). Some tissue specificity in αGal expression
does exist in certain mammals. In rats, Griffonia simplicifolia B4 isolectin (BS





IB4), a molecule with high specificity for α-D-galactose groups, was found to bind
to deeper layers in the epidermis and not at all in higher layers of the skin (Brabec
et al., 1979). The quantity of αGal residues expressed on tissue is also variable by
host species and by the type of the glycoconjugate. For example, bovine
thyroglobulin has approximately 11 residues of αGal per molecule while Saimiri
(squirrel monkey) expresses one residue per thyroglobulin molecule and mice
express one αGal residue per every four thyroglobulin molecules (Thall and
Galili, 1990).

As expected, Macaca (macaque) and humans do not express a terminal galactose
α(1,3) linked to a penultimate galactose (Gal-Gal linkage) on thyroglobulin, or to
any other issue, because they have an inactive GGTA1 gene. In humans, only
three glycoconjugates found in red blood cells (RBCs) are known to express a
terminally linked α-galactosyl: CTH, P1 and B antigen. CTH and P1 have an
α(1,4) linkage and B antigen has a fucose attached to the penultimate galactose
(Galα1,3Fucα1,2). BS Lectin can bind the terminal residue of the human blood
B-antigen, but anti-gal binding—which is highly specific for the Gal-Gal
linkage—is blocked due to the branched fucose (Galili et al., 1984). Still, humans
that express the B antigen (OB, BB or AB blood type) have reduced levels of IgG
anti-Gal, possibly because there is some level of reaction between the antibody
and the terminal galactose monosaccharide (McMorrow et al., 1997).





Of interest is the de novo-expression of αGal that has been observed on humans
cells, including: senescent RBCs, pathologic RBCs such as those derived from
thalassemic or sickle cell anemia-affected individuals (Galili et al., 1984) and
cells from human mammary carcinomas (Castronovo et al., 1989). Additionally,
lung carcinoma cells will sometimes secrete β-interferon containing αGal
carbohydrate chains (Kagawa et al., 1988). In this way, αGal could play a role in
autoimmune disease as human RBCs expressing αGal are targeted and lysed by
anti-Gal mediated-complement lysis (Galili, 1993). In humans, the GGTA1 gene
is not transcribed, and although mice and pigs have alternative genes that can
synthesize very small quantities of αGal epitopes (Milland et al., 2006), no other
human gene has been discovered that can do this. In the case of senescent RBCs
expressing αGal, displaced GT-positive gut bacteria or their GTs can make their
way into the circulatory system and become the source of αGal found on human
RBCs (Hamadeh et al., 1996). RBCs exposed to Klebsiella bacteria and their
galactosyltransferases have been shown to incorporate bacterial αGal residues on
their surfaces (Hamadeh et al., 1996). Older RBCs compared to younger cells
may be more likely to acquire αGal because their extended time in circulation
exposes them to more lactosmaine acceptor molecules that can link αGal
molecules (Hamadeh et al., 1996). Aberrant expression of αGal in other human
tissues could indicate that within these tissues inactivation of GGTA1 may not be
absolute, or a functional form of the polypeptide can be made under certain
conditions (Galili et al., 1984).





Catarrhines without a functional GT gene still have homologous sequences to
GGTA1. Two GGTA1 homologs have been found in catarrhines by using probes
from cDNA sequences derived from pigs, cattle and rodents (Jozaisse et al., 1991;
Strahan et al., 1992; Koike et al., 2002). The two loci evolved independently in
the Haplorrhine (monkeys, apes and tarsier) lineage. All haplorrhines have an
orthologue of the gene, a processed pseudogene (PPG) that does not result in
production of a functional protein (Larsen, et al., 1990; Jossaize et al., 1991;
Koike et al., 2007). The PPG appeared in the primate genome approximately 57.6
Ma, after the Strepsirrhine/Haplorrhine split, but likely prior to tarsier divergence
from the rest of the haplorrhines. Putative grouping of the tarsier’s GT gene
sequence places it with the PPG sequence (Koike et al, 2007). Catarrhines still
express the PPG and also an altered GGTA1 gene referred to as an unprocessed
pseudogene (UPG) (Jozaisse et al, 1991; Koike et al., 2007). The human
homologues are found on chromosomes 12 (PPG) and 9 (UPG) (Jozaisse et al.,
1991).

Comparisons of the human UPG with sequences from Macaca and mouse GT
genes show little homology in various portions of the regulatory region (Koike et
al., 2001; Koike et al., 2002). The same is observed with comparisons of the
regulatory regions (exons 1-3) of the more distantly related pig and mouse
GGTA1 genes (Koike et al., 2001). Although these differences affect gene
regulation in pigs and mice, the enzymatic function is identical in both species
(Koike et al., 2001), indicating that conservation in the regulatory region is not





essential for gene function. In contrast, homologous genetic sequences in coding
regions of the GT gene between primates, mice and bovine have been found
(Larsen et al., 1990; Galili and Swanson; Jozaisse et al., 1991), indicating that the
coding region is conserved. In primates, including Homo, Pongo (orangutan),
Macaca and Callithrix (marmoset), homology in the gene-coding regions (exons
4-9) between apes and Callithrix was 94.7% and between Macaca and Callithrix
was 92.4% (Koike et al., 2002).

Several mutations in the coding regions of the Homo, Callithrix and Pongo genes
(exons 7, 8 and 9) independently result in GT gene inactivation, but two
mutations that independently yield a truncated gene product are shared by all
three species: (1) a deletion on exon 7, and (2) a nucleotide substitution on exon 9
(Koike et al., 2002). Nucleotide alignment of genetic sequences that included
strepsirrhines, platyrrhines, cercopithecoids, and hominoids indicate the point
mutation on exon 7 in the catarrhine sequences, upstream of a region specifying
an enzymatic catalytic domain, was likely responsible for GGTA1 inactivation
(Koike, 2007). The presence of the same mutation in cercopithecoids and
hominoids, clocked at approximately 28.1 Ma, indicates that the gene was
inactivated prior to an OWM-ape lineage divergence (Koike et al., 2007).

It is of interest that KO pigs and KO mice still express relatively low quantities of
αGal epitopes compared to their WT counterparts as a result of iGb3S
glycosyltransferase activity (Milland et al., 2006). Like α-galactosyltransferase,





this enzyme is part of the ABO-blood group family of glycosyltransferases and
can catalyze the placement of a terminal Gal residue on glycoconjugates;
however, in contrast to αGT enzyme activity, αGal capping via iGb3S is restricted
to acceptors on iGb3 glycolipids (Milland et al., 2006). This is of general interest
because αGal is the major xenoantigen that induces hyperacute rejection in organ
transplants to humans that come from pigs (Phelps et al., 2003). Therefore, organs
from GT KO pigs may still be immunogenic. This is of consequence to our
current research because deciphering pathogen-host cell protein interactions may
largely depend on absolute expression or non-expression of the protein of interest.
Results must be interpreted in this context.

2.2 Anti-Gal
Catarrhines produce very high amounts of anti-gal antibodies that recognize the
Galα1,3Galβ1,4GlcNAc-R epitope with high affinity (Galili et al., 1984; Galili et
al., 1988). In humans, anti-Gal is most commonly found as class IgG (IgG1,
IgG2a, IgG2b, IgGc subclasses) comprising approximately 0.5-1.0% of total serum
IgG (Galili et al., 1984), but it is also produced as classes IgM and IgA
(LaTemple and Galili, 1998). Humans produce other naturally occurring IgG
molecules in blood, including anti-blood A and B and anti-T antibodies, that
similar to anti-gal, display an anti-carbohydrate specificity (Galili et al., 1984).
Production of natural antibodies is attributed to constant exposure to naturally
occurring antigens over evolutionary time. The constant exposure to
gastrointestinal flora that expresses αGal on the cell wall, such as E. coli,





Salmonella and Shigella (Galili et al., 1988; Hamadeh et al., 1992), may stimulate
the observed production of anti-Gal throughout the lifetime of humans as well
(Galili et al., 1984).

Besides commensal and pathogenic gut bacteria, a variety of other pathogens also
express αGal residues, including protists (Ramasamy and Rajakaruna, 1997;
Pingel et al., 1999). Species of trypanosomatids (Leishmania sp. and
Trypanosoma cruzi), the causative agents of leishmeniasis and Chagas disease,
express lipids capped by galactosyl residues on the parasite’s surface during part
of its life cycle, and infected hosts show significant increases in anti-Gal
production compared to uninfected individuals (Avila et al., 1989). Some
individuals also develop a class of highly specific anti-Gal antibodies to the T.
cruzi trypomastigote (the infective stage) that efficiently inhibits parasite growth
through complement-mediated damage (Almeida et al., 1991). The merozoites
(infective stage) of Plasmodium falciparum, the most virulent malarial parasite of
humans, also express αGal antigens and induce antibody-dependent complementmediated lysis (Ramasamy and Rajakaruna, 1997; Ramasamy et al., 1999).
During egress from host cells, enveloped viruses often incorporate cellular
membrane components into or onto the particle; and this includes galactosylcapped entities (Welsh, 1977; Welsh et al., 1998). Viruses that express αGal then
become antigenic to GT-negative species. In this way, anti-Gal is speculated to
restrict xenotransmission of viruses propagated in GT-positive species by





targeting them for complement-mediated inactivation (Welsh et al., 1975; Welsh
et al., 1976; Welsh et al., 1978; Repik et al., 1994; Rother et al., 1995; Takeuchi et
al., 1996; Kim et al., 2007).

Mammalian species that naturally express GGTA1 accordingly do not make antiGal, and are therefore tolerant to αGal-expressing viruses (Rother et al., 1995;
Welsh et al., 1975; Welsh et al., 1976). It is speculated that natural anti-Gal
production was an adaptive response to pathogenic infection for catarrhine
primates (Galili et al., 1987; LaTemple and Galili, 1999; Rother and Galili, 1999).
However, for anti-Gal expression to be a driving force behind GT gene
inactivation, anti-Gal production would have had to occur concurrently with the
GGTA1 loss-of-function mutations. Experimental mice that are double knockouts
for the GGTA1 gene (Thall et al., 1995) do not naturally produce anti-Gal in sera
and only produce low levels of IgG and IgM antibodies after initial exposure to
antigenic epitopes (LaTemple and Galili, 1998). A robust antibody response,
comparable to titer levels found in humans, is only achieved by multiple
immunizations (LaTemple and Galili, 1998). This may indicate that upon
historical loss of GT activity, anti-Gal-mediated protection was not immediate or
wholly effective on primary exposures to αGal-expressing pathogens. For a
period of time, prior to the natural production of anti-Gal in the absence of
external antigen stimulation, catarrhines still would have been highly susceptible
to pathogens that expressed αGal epitopes. As such, I suggest it is more plausible
that production of natural anti-Gal occurred after inactivation of GGTA1.





I hypothesize that loss of GT gene expression may have been a response to
pathogen-mediated selection on host genotype (GGTA1) or phenotype (αGal).
Pathogens often utilize host cellular carbohydrates as binding receptors or in other
capacities during the course of an infection. The terminal carbohydrates that
decorate cell surfaces function in various biological capacities for the host
organism. Due to their location at the outer edges of cells, carbohydrates are
prime candidates for mediating interactions with other cells, other molecules, and
with environmental agents. As targets to foreign agents, surface sugars are
expected to be under constant evolutionary pressures and are therefore key
players in organismal health and disease.

2.3 Terminal carbohydrates
Many forms of life, including bacteria, plants and animals, express carbohydrate
chains on the exterior surfaces of their cells. The repertoire of glycans and the
function they perform varies significantly depending on species and tissues, but
the distribution of these structures in nature is indicative of their fundamental
biological role. Between 1-2% of animal genes are involved in glycan
modification or synthesis (Bishop and Gagneux, 2007). Relative to bacteria and
plants, animals utilize a restricted set of carbohydrate units to create diverse and
complex structures, generally arranged as four basic types of glycoconjates: Nlinked, O-linked, glycolipids and proteoglycans (Bishop and Gagneux, 2007).
Patterns of glycan distribution can be limited to single species, be lineagespecific, be similar across distantly related species or be widely conserved





(Bishop and Gagneux, 2007). The different distribution patterns likely resulted
from various processes such as the evolution of independent lineages following
phylogenetic splits or from selection pressures imposed by pathogens (Bishop and
Gagneux, 2007).

2.4 Pathogen and host-cell glycan interactions
During the course of infections, pathogens are involved in a variety of interactions
with terminal carbohydrates on host cell surfaces and have evolved numerous
strategies to exploit them. Pathogens can also utilize glycosyltransferases to
modify their own proteins, and this may result in increased virulence for that
pathogen (Bishop and Gagneux, 2007). Pathogens have also evolved ligands
(lectins) that bind host carbohydrates, and they also produce molecules that mimic
host glycans and can then bind to corresponding host ligands (Bishop and
Gagneux, 2007). Viruses, especially enveloped viruses, can also incorporate host
cell carbohydrates or even proteins on their envelopes during egress. This can aid
to promote their infection cycles and also provide reduced immunogenicity in the
host (Vigerust and Shepherd, 2007). Host cell surface glycans are preferred
binding sites for viruses to utilize as receptors (Olofsson and Bergström, 2005).
Among these binding sites is heparan sulfate, a heavily glycosylated protein found
on the surface of animal tissues. Heparan sulfate often serves as initial binding
sites for various mammalian viruses, including: Foot and mouth disease virus
Type O (Jackson et al., 1996), Dengue virus and yellow fever virus (Germi et al.,
2002), herpes viruses (WuDunn and Spear, 1989), and Sindbis viruses (Byrnes





and Griffin, 1998). Other commonly exploited epitopes are sialic acid
monosaccharides. The carbohydrate chains of sialic acids are structurally very
similar to αGal glycans (Fig. 2). It is possible that αGal molecules play a role
analogous to sialic acid during pathogen infection.

Sialic acids are the most commonly expressed terminal carbohydrates on cells of
vertebrates (and other animal phyla) and are essential for embryonic development
(Varki, 2010). Sialic acid residues are transferred to glycoconjugates by
sialyltransferases. Both sialyltransferases and α-galactolystransferases function
within the trans-golgi network and link terminal residues to N-acetyllactosaminyl
Galβ1,4GlcNac-R carbohydrate chains (Joziasse et al., 1991; Thall and Galili,
1990). This results in competition for linkage of the terminal unit (either sialic
acid or αGal) to the common acceptor (Gorelik et al., 1995). It is of interest to
consider that because α-galactosyl residues can utilize the same position on
glycoconjugates as sialic acid, they may perform corresponding functions during
pathogen infections, and may also be subjected to similar evolutionary pressures.
During evolution, certain linkage expression patterns of sialic acid in specific
vertebrate taxa underwent major genetic changes, but the same domains remained
conserved for millions of years in the majority of vertebrate taxa, including
closely related species (Gagneux et al., 2003). This indicates that selective
pressures on these domains may be species or lineage-specific. The primate
evolutionary record yields good evidence of alterations of sialic acid loci under





selection in response to pressures exerted from pathogens, notably the ST6 betagalactosamide alpha 2,6-sialiyltranferase 1 (ST6GAL1) gene and cytidine
monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene.

Figure 2: αGal residues on a carbohydrate chain (top) and sialic acid-capped
carbohydrate chain (bottom), as part of glycoproteins or glycolipids on the surface
of mammalian cells.

2.4.1 Alpha 2,6 linked sialic acid and influenza A
Influenza A and B viruses are among several viruses that can use sialic acid as an
attachment receptor to gain entry into host cells (Varki and Varki, 2007), and they
also encode their own sialidases (sometimes called neuraminidases) to facilitate
their release from these cells (Weis et al., 1988; Susuzki et al., 2000). Influenza A
viruses attach to host cell terminal sialic acid residues via the haemagglutin (HA)
glycoprotein on their surfaces; therefore, virus host range is defined by the
receptor binding site of the HA they express (Vines et al., 1998; Angata and
Varki, 2002). HA of avian influenza A viruses generally recognize different
carbohydrate linkages (SAα2,3Gal) than human influenzas (SAα2,6Gal) do,
possibly because the linkages orient the terminal carbohydrate in an energetically
favorable position (Vines et al., 1998). Among primate taxa, certain influenza



viruses cause disease in humans but not in other great apes, and vice versa
(Gagneux et al., 2003). This is because influenza viruses infecting the other great
apes use SAα2,3Gal linkage specificity (Gagneux et al., 2003; Varki and Varki,
2007). Humans express SAα2,3Gal linkages but these sites are found lower in the
airways relative to SAα2,6Gal sites, and virus may not travel that far down during
host exposure (Varki and Varki, 2007). It is hypothesized that the ST6GAL1
gene, the gene responsible for the enzyme that biosynthesizes the placement of
the terminal sialic acid to α2,6Gal, has undergone altered regulation in the
hominin lineage (Gagneux et al., 2003), to become the predominantly expressed
sialic acid linkage in the upper airways. Avian influenzas can sometimes cross
the species barrier via an intermediate host—pigs—which express both
SAα2,3Gal and SAα2,6Gal domains on the upper respiratory airways (Varki and
Varki, 2007). The lack of SAα2,3Gal expression in human upper airways is fairly
protective against direct transmission; the 1918 influenza pandemic is an example
of a successful transmission event of a bird virus to the human population that
could utilize both α2,3Gal and α2,6Gal linkages (Varki and Varki, 2007).

2.4.2 NeuAGc and Malaria
The vector-borne apicomplexan, Plasmodium falciparum, is the causative agent
of the most virulent form of malaria in humans. P. falciparum evolved from P.
reichenowi, the malarial parasite species that infects our closest living relatives,
chimpanzees (Pan troglodytes and P. paniscus) (Rich et al., 2009). Pan, like
other apes and most other mammals (except humans), express the terminal sialic





acid Neu5Gc, and in smaller quantities also its metabolic precursor Neu5Ac, on
erythrocytes (Chou et al., 1998; Hayakawa et al., 2001). The infective stage of
Plasmodium, the merozoite, invades host erythrocytes primarily via binding the
host glycoprotein A (GYPA) receptor that is capped by sialic acid (Martin et al.,
2005). P. reichenowi preferentially utilize the sialic acid, Neu5Gc, to cause
infection in chimps, but P. falciparum binds Neu5Ac in humans (Orlandi et al.,
1992). This is because between 2.8 and 3.2 Ma, prior to the appearance of Homo,
an exon deletion in the cytidine monophosphate (CMP) N-acetylneuraminic acid
hydroxylase (CMAH) gene responsible for conversion of Neu5Ac to Neu5Gc,
rendered our ancestors unable to produce the Neu5Gc terminal domain (Chou et
al., 1998; Hayakawa et al., 2001: Hayakawa et al., 2006). Only Neu5Ac, the most
common sialic acid found in modern day humans, accumulates on RBCs
(Hayakawa et al., 2001; Rich et al., 2009), while the Neu5Gc residue is now
antigenic (Brinkman-Van der Linden et al., 2000). It is hypothesized that
pressure from the ancestral P. reichenowi parasite may have driven selection for
the mutated gene during hominin evolution that then provided natural resistance
to infection (Rich et al., 2009). For some time, our ancestors would have enjoyed
reduced susceptibility to malaria, but subsequently, prior to ~10,000 years ago, a
population of P. falciprum had evolved binding specificity for Neu5Ac, and
malaria, abetted by agriculture, once again became a major human pathogen
(Hayakawa et al., 2001; Rich et al., 2009). In modern human populations, the
sialylated GYPA domain is highly polymorphic. This suggests that even today,
this site is under high selection, presumably due to continued pressure exerted





from Plasmodium (Martin et al., 2005) or numerous other pathogens that can
exploit this moiety. These include various viruses such as Newcastle disease
virus, Sendai virus and human parainfluenza viruses (Angata and Varki, 2002).
Although the sialyltransferase responsible for addition of Neu5Ac to glycan
chains is under evolutionary constraint, modification of the GYPA protein
scaffolding has been an effective host strategy for pathogen evasion (Martin et al.,
2005).

It is of special interest, and is perhaps not unexpected, that changes in
glycosylation may exert wide-ranging effects on the organism and these effects
may themselves be of evolutionary significance. Siglec-1 (sialic acid binding
immunoglobulin superfamily lectin) is found in all mammals and has strong
binding affinity for Neu5Ac (Brinkman-Van der Linden et al., 2000). Since the
inactivation of the CMAH gene, human tissue provides abundant ligands for this
lectin, and its expression is especially notable on macrophages in splenic tissue.
The localization and expression of siglec-1 may provide humans an advantage
against sialic acid-expressing pathogens, increasing their recognition by
phagocytic cells (Brinkman-Van der Linden et al., 2000). Other studies with
knockout mice for the CMAH gene show that loss of Neu5Gc expression in mice
yields phenotypes that appear, to some degree, to have analogues in humans.
Compared to control mice, Neu5Gc-deficient mice have age-related hearing loss
and slow wound healing; these are derived traits also associated with humans after
divergence from our common (CMAH gene-expressing) ancestors with





chimpanzees (Hedlund et al., 2007).

Perhaps of more significance is the

possibility that Neu5Gc, which is expressed in low quantities in the brain of apes
and other mammals, may have restricted brain expansion in ancestral primates
(Varki, 2001; Chou et al., 1998; Chou et al., 2002). The fixation of the gene,
sometime by 2 Ma, coincides with a significant increase in hominin cranial
capacity as evidenced by the fossil record (Chou et al., 2002). Lastly, molecular
analyses of CMAH gene sequences between different human ethnic groups, Pan
and Gorilla, have even been employed in assessing hominin dispersal out of
Africa and in reconstructing modern human origins (Hayakawa et al., 2006).

2.5 Experimental mouse models
Cellular functions, as studied in vitro, may not always translate accurately to
functional studies in a complex system. Cell lines can be very useful for testing
questions about phenomena at the cellular or molecular level, but for questions
that concern evolution, it is essential that in vitro findings be verified at the
organismal level. Ideally, research based on a species of interest would also be
tested on that animal species, as they are the test subjects. However, several small
mammal species are used as models in biological research in lieu of the species of
interest, which is often humans. It is neither ethical nor always feasible to
experiment directly on humans. Codes of ethics in research also extend to our
closest relatives, nonhuman primates, because, among other concerns such as cost
and availability, many primate species are endangered.





Mice are among the most commonly used animal models in experimental research
because they are less expensive, are easier to genetically manipulate and have
faster reproduction times with more numerous litters compared to larger
laboratory mammals (Messaoudi et al., 2011; Bähr and Wolf, 2012). These traits
are especially beneficial when a great number of experiments must be completed.
However, a major criticism of utilizing mice is that they are not suitable
substitutes for studying the biology of other organisms (most notably humans)
due to their genetic distance from humans. Additionally, inbred laboratory mice
do not generally harbor the same species of pathogens as humans, and for disease
research this limits the diversity of pathogens and variability in responses from
host mice that can be examined (Messaoudi et al., 2011). Despite these
limitations, a remarkable amount of information about fundamental cellular and
molecular functions is known from using mouse models (Messaoudi et al., 2011).
Because of the relative ease of genetic manipulation, mice with desired mutations
often can be generated for studies of human issues (Crawley, 1999), and the
mutated homologous loci result in genetic and phenotypic similarities in mice and
humans (Bedell et al., 1997). Laboratory mice are even useful for studies of
nonhuman primates, and serve as models for one of the most severe pathogens
affecting nonhuman primates, Ebola virus (Bray et al., 1998; Bradfute et al.,
2012). For my dissertation research, working with a nonhuman primate model
was not possible due to cost and laboratory capabilities. Fortunately, geneticallyaltered mice were readily available for testing the proposed hypotheses.





2.6 Viruses
Two groups of viruses were predominantly used in this study to understand the
role of GGTA1 activity and the terminal carbohydrate, αGal, in the course of viral
infections: 1) Sindbis (SINV) group of viruses and 2) herpes viruses. Clearly, the
viruses examined in this study would not have been the putative selection agents
of 28 million years ago. As with any study focused on reconstructing the
evolutionary past, it is not possible to directly evaluate the selection agents or the
effect these agents may have had on primates millions of years ago, but we can
make inferences based on strongly supported data. Therefore, this study should
be taken as a proof of principle of what could have happened, rather than a factual
account of what did occur.

2.6.1 Sindbis virus (SINV) and SINV-related viruses
The arthropod-borne alphaviruses are distributed worldwide: Old World
alphaviruses include Sindbis (SINV), West Nile (WNV), Semliki forest (SFV)
and Chikungunya (CHIK) viruses, and New World alphaviruses include Eastern
equine encephalitis (EEE) and Western equine encephalitis (WEE) viruses
(Strauss et al., 1994). The prototype alphavirus, Sindbis virus, is an enveloped,
positive-sense RNA virus with a genome of 11,703 nucleotides (Strauss et al.,
1994). SINV (strain AR339) was originally isolated from the Culex mosquitos in
Sindbis, Egypt in 1952 (Taylor et al., 1955), but it is geographically widespread,
and has been collected from infected mosquitos in Europe, Africa, Asia and
Australia (Johnson, 1965; Kurkela et al., 2008). Culex and Culiseta mosquitos are





primary vectors of SINV (Taylor et al., 1955; Johnson, 1965; Kurkela et al.,
2008), although ixodid (hard) tick transmission has been documented (Taylor et
al., 1955; Gresikova et al., 1978). Various avian species, including game and
passerine birds, serve as reservoirs for the virus (Taylor et al., 1955; Sammels et
al., 1999; Kurkela et al., 2008), and it is possible that the geographical
dissemination of the virus is due to the migrations of viremic birds (Sammels et
al., 1999; Kurkela et al., 2008). A broad range of animal hosts, such as
amphibians and mammals (including humans), are susceptible to SINV (Johnson,
1965). In humans, disease from SINV infections can range from asymptomatic to
chronic, and although generally not a health threat, epidemics have occurred in
Europe and Africa (Sammels et al., 1996; Kurkela et al., 2008).

In mice, SINV is neurovirulent and is generally fatal if the virus reaches the
central nervous system (CNS), but infection is restricted if only extraneural tissue
is involved (Johnson, 1965). The virus replicates in skin, skeletal muscle and
fibroblast tissue, and then disseminates to the CNS via a viremia (Klimstra et al.,
1998; Ryman et al., 2000). Lesions occur in both skeletal muscle and in the CNS,
but there is no significant pathology in infected liver or abdominal organs (Taylor
et al., 1955). In the brain, SINV induces apoptosis in spinal cord and brain cells
(which do not regenerate), and the loss of this tissue correlates with death in mice
(Lewis et al., 1996). Most strains of SINV are lethal to neonatal mice, replicating
to very high levels and causing ataxia and death by five days post infection
(Taylor et al., 1955; Klimstra et al., 1998). In weanling mice, the virus has a





prolonged incubation period that results in delayed onset of symptoms (Taylor et
al., 1955); by approximately two weeks of age, mice have reduced viral load and
no longer succumb to infection (Taylor et al., 1955; Reinarz et al., 1971; Lewis et
al., 1996). In these mice, virus replication and viremia are limited primarily by a
robust IFN-α/β response, which increases with age (Ryman et al., 2000).

SINV are easily adaptable to a variety of cells in vitro, and strains used in
laboratory settings can be modified by their cell culture passage history
(McKnight et al., 1996). For example, the virus can acquire the ability to utilize
heparan sulfate as an attachment receptor when grown in BHK cells, even after
one passage (Klimstra et al., 1998). SINV viruses may also become attenuated
after serial passage (McKnight et al., 1996). Additionally, SINV isolates, mutants
or laboratory strains may differ in their level of virulence in young and adult mice
(McKnight et al., 1996). S.A.A.R86 (South African arbovirus no. 86) is a natural
virus isolate of the SINV group of alphaviruses and is genetically distinct from
the wild-type (WT) AR339 strain (Heise et al., 2000; Ryman et. al, 2000). This
isolate is neurovirulent and lethal to adult mice when inoculated intracranially
(i.c.) (Russell et al., 1989; Ryman et al., 2000); this is due to a mutation in its
nonstructural protein 1 (Heise et al., 2000). The TR339 strain is a laboratorygenerated clone that is similar to AR339, but expresses cell-culture adaptive
mutations such as heparan sulfate binding, and is more virulent to neonatal mice
compared to culture-adapted strains (McKnight et al., 1996). The TE12-GFP





mutant is a recombinant virus encoding a green fluorescent protein (GFP) gene
under control of a subgenomic promoter (Wang, 2008). The GFP mutant
replicates to similar titers as the parental TE12 mutant (Wang, 2008). TE12-GFP
was constructed from the (avirulent) Toto1101 and (virulent) NSV strains and is
highly lethal to suckling mice, but not adult mice (Lustig et al., 1988).

2.6.2 Herpes viruses
The alphaherpesviruses, herpes simplex virus type 1 (HSV-1) and type 2 (HSV2), are large, double stranded DNA viruses that are ubiquitous human pathogens.
These viruses cause primary (lytic) infections in skin and mucosal epithelia and
then travel to the peripheral and central nervous system where the viruses
establish latent infections in ganglia (Sodeik, 2007). Lytic infections can recur
when the virus reactivates and travels back to the peripheral sites of infection
(Sodeik, 2007).

Mice serve as models for infections of these human pathogens (Baker and Plotkin
et al., 1978; Manickan and Rouse, 1995). The pathogenesis and neuroviruluence
of HSV-1 and 2 can differ, as shown in experimental mice. This is often a
consequence of the route of infection. By intravaginal infections, both virus
strains produce infections in the vulva and vagina, without much involvement of
peripheral organs. The virus then disseminates to the CNS where infection can
lead to fatal encephalitis (Renis et al., 1976). Almost any route of inoculation
with HSV-2 results in apparent hepatic necrosis, but similar infections with HSV1 seldom result in liver involvement or damage (Mogensen et al., 1974; Renis et





al., 1976). Severe infections with herpesviruses in humans (e.g., HSV-2, VZV,
EBV) often involve dissemination to various organs and exhibit liver pathology
(Renis et al., 1976).

The HSV-1 GFP (KOS 1.1) strain is a mutant that expresses a GFP-ICP8 fusion
protein. The ICP8 protein, an early DNA-binding protein that functions in viral
nucleic acid and protein localization to replication compartments, as well as
regulation of late gene expression in host cells, is mutated in this recombinant
virus (McNamee et al., 2000). The virus is able to effectively initiate infection,
but DNA replication and late gene expression in host cells are affected, and
subsequent virus production is significantly reduced compared to that of wild type
HSV-1 (Gao and Knipe, 1991; McNamee et al., 2000; Taylor et al., 2003).

The murine gammaherpes virus 68 (γMHV-68) is a member of the
gammaherpesviruses. The virus is closely related to the human Epstein-Barr virus
(EBV; the most common agent of mononucleosis) and Kaposi’s sarcomaassociated herpesvirus. In mice, infections with γMHV-68 most commonly occur
through the nasopharyngeal tissue, and the virus replicates in the lung epithelial
cells (Michaud et al., 2010) where it can cause lymphoproliferative disease
(Sunil-Chandra et al., 1992). During primary infection, the virus can be recovered
from the lung and various peripheral tissues such as kidneys and spleen (SunilChandra et al., 1992). In the spleen, the primary organ where virus persists,
infection leads to enlargement of the organ (splenomegaly) (Sunil-Chandra et al.,





1992). Latent infection occurs when the virus migrates from lung and other
tissues to B lymphocytes (as seen with EBV infections in humans) and
macrophages (Sunil-Chandra et al., 1992; Michaud et al., 2010). Several months
to a year after infection, mice can develop lymphomas or lymphoproliferative
disease (Sunil-Chandra et al., 1992).





CHAPTER 3
METHODS AND MATERIALS

3.1 Cell lines
For in vitro studies, three pairs of cell lines (two mouse lines and one human line)
were used to verify that findings were not unique to a single type of cell line or
organism from which the cell line derived. The GT KO mouse embryonic
fibroblast (MEF) cell line is derived from GT-deficient transgenic mice and
therefore lacks expression of αGal. MEFs from 129 WT mice (GT-sufficient)
(Jones et. al., 1996) were acquired from Dr. Stephen Jones at UMMS, as controls.
Both cell lines were cultured as monolayers in 10cm petri plates because 129 WT
MEFs appear to grown better in dishes than in flasks. Cultured cells were fed
with GIBCO Dulbecco modified Eagle’s medium (EMEM) and supplemented
with 10% fetal bovine serum (FBS) and 2.5% penicillin and streptomycin and
2.5% L-glutamine. WT 129 cells produce debris after initial passages, so they
were used after third passage for experiments, but after 4-5 passages, cells were
no longer viable for experimentation.

A pair of modified human melanoma cell lines, the SK-N-MC cells (Biedler et al.,
1973), were transduced with a retroviral vector containing a full-length porcine
GT cDNA (pLGTSN) or a retroviral vector without insert (pLXSN) (Welsh,
1998). The GT-modified human cell lines were designated as SK-N-MC pLXN





(SK) (inactive GT gene) and SK-N-MC pLGTSN clone 10 (SK-GT) (active GT
gene). These cell lines were grown in GIBCO Roswell Park Memorial Institute
(RPMI) medium 1640 and supplemented with 10% fetal calf serum (FCS) and
2.5% penicillin and streptomycin, 2.5% L-glutamine and the selective antibiotic
for the Neomycin resistance gene, G418 (500μm/mL).

The BL6 (bladder 6) cell line, a subclone of the highly invasive B16 melanoma
cell line, was isolated from the bladder wall of C57BL/6J mice (Hart, 1979; Poste
et al., 1980). Continuous selection for metastatic capabilities resulted in BL6
cells that spontaneously lost biosynthetic αGT activity (Gorelik et al., 1995).
These melanoma cells were later transfected with the murine α1,3GT gene cDNA
to create a cell line, designated BL6αGT, with similar characteristics to the
parental cell line except for αGal expression on the cell surface (Gorelik et al.,
1995). We used the BL6αGT (GT+) cell line as controls for BL6 (GT-) cells.
Both cell lines were cultivated as monolayers in GIBCO minimum essential
medium (MEM) and supplemented with 10% fetal calf serum (FCS) and 2.5%
penicillin and streptomycin and 2.5% L-glutamine. The stable transfectant
BL6αGT line seems to maintain the inserted gene without selection media, but the
antibiotic G418 can be utilized to reduce the possibility it will lose the gene (U.
Galili, pers. comm.). Cells were maintained by freezing at -80° in aliquots of
approximately 1x106 cells/vial, in 90% fetal calf serum and 10% DMSO. Two
different clones of the BL6 and BL6αGT cell lines were used throughout the
course of the study, because the initial set of cells acquired began exhibiting





differences in morphology and growth rates, and BL6αGT displayed variable
expression of αGal on its’ surface. The second set of cells appeared more stable.
Several experiments initially completed on the first set of cells, such as time
courses and adsorption assays, were repeated on the second set. Results were
consistent in both sets of cell lines.

SK and SK-GT cell lines were tested for surface expression of αGal by staining
with monoclonal anti-gal antibody, M86 (Enzo Life Sciences), and secondary
allophycocyanin (APC)- or R-phycoerythrin (R-PE)- conjugated goat anti-mouse
IgM (Invitrogen). BL6 and BL6αGT were regularly monitored for αGal
expression during the course of the study with M86 and secondary APC or R-PE,
or alternatively, with fluorescein isothiocyanate (FITC)-conjugated BS lectin
(BSl-B4) from Bandeiraea simplicifolia was used as an αGal binding lectin
(Sigma-Aldrich). BSl has broader specificity than anti-gal, as it has binding
capacity to the GalNAc and Galα1,4Gal carbohydrates, but anti-Gal is specific
only to a galactose in an α(1,3) linkage to a penultimate galactose (Galili et. al,
1984). BSl can also bind to Galα1,3Fucα1,2Gal, as demonstrated by
hemagglutination of erythrocytes derived from Hylobates and Pongo (Galili et al.,
1987). Fluorescence was measured using a BD Biosciences LSR II flow
cytometer with FACS Diva software and analyzed using FlowJo software
(TreeStar Inc., Ashland, OR).





3.2 Knockout mice
GT KO mice [C57BL/6J x DBA/2J x 129sv] were generated by disruption of the
α1,3GT gene by homologous recombination (Thall et al., 1995). GT KO mice
were backcrossed onto the C57BL/6J background for well over ten generations in
the laboratory of Dr. Uri Galili in the Department of Medicine at UMMS.
Breeding pairs were kindly donated to our laboratory, and mice were bred at the
UMMS animal facilities. Adult C57BL/6J mice, acquired from Jackson
Laboratories, were used as control mice. C57BL/6J (B6) suckling mice were bred
at the UMMS animal facilities. During the course of this study the GT KO mice
generally bred well, with litter sizes that ranged between 2-10 pups, and mice
only displayed occasional periods of reduced reproductive output. The mice
showed no outward signs of abnormal health conditions, except a few incidents of
dental malocclusion and rare cases of hydrocephaly or rectal prolapse.

3.3 Mouse crosses
Different mouse strains have variable resistance to HSV infections (Kastrukoff et
al., 1985). Both 129 and DBA/2 mice are genetically more susceptible to HSV
infections than B6 mice. Because B6 mice are utilized as controls to KO mice in
in vivo experiments, any underlying susceptibility that is a result of the KO
genetic background would skew results. The backcrossing history of KO mice
into the B6 line suggests that the disrupted GGTA1 locus should be well
recombined into the B6 genotype. However, further outcrossing and backcrossing
mice will provide some assurance that our loci of interest will further recombine





into the B6 background and that possible genetic linkages from the DBA/2 and
129 backgrounds will be disassociated. Male C57BL/6J mice were mated with
female GT KO to produce an F1 heterozygous generation. The heterozygotes
maintain active GT expression. Backcrosses (F1xWT and F1xKO) were then
created by mating the F1 generation with individuals of the parental strains. All
F1xWT crosses had functional GT expression while F1xKO crosses had a 50%
probability of being homozygous for the KO gene. It would be expected that the
susceptibility of an F1xKO mouse that inherited two alleles of the inactive α1,3GT
locus would respond in the same way as a GT KO animal, to herpesvirus
infection. F1xF1 intercrossed mice were also created, but were utilized in few
experiments. All mice were analyzed for GT activity by
testing for surface expression of αGal. Anti-Gal or BS lectin binding of
peripheral or cardiac blood cells was performed; BS lectin was more adequate for
testing αGal expression in blood.

3.4 Enveloped viruses
The following enveloped viruses were predominantly used in these studies:
Sindbis virus (SINV) HR strain (Burge and Pfefferkorn, 1966); S.A.A.R86,
TR339 and TE12-GFP strains obtained from Dr. Dennis T. Brown at North
Carolina State University; herpes simplex type 2 (HSV-2) strain MS (Rosenberg
et al., 1972); herpes simplex type 1 (HSV-1) KOS1.1 strain (Babu et al., 1996)





obtained from Dr. David Knipe, Harvard; HSV-1 KOS 1.1 GFP (green
fluorescent protein) ICP8 mutant (McNamee et al., 2000) obtained from David
Knipe; mouse γ-herpes virus-68 (γMHV-68) obtained from Dr. Blake Tomkinson.

Table 1 shows additional viruses that were screened during the study. These
viruses were readily available for use in the laboratory of Dr. Raymond Welsh at
the UMMS. Viruses were grown in Vero cells, which do not express αGal;
therefore the carbohydrate was not expressed on the viral envelope. Several
SINV and herpes viruses were also grown in L929 cells for experiments where
αGal expression on the viral envelope was needed. Additionally, murine
cytomegalo virus (MCMV), strain Smith, was grown in GTKO cells that do not
express αGal and had an initial stock titer of 3.5x107.





TABLE 1: Viruses screened during this study

a

Viral stocks were grown in either αGal-negative Vero cells or αGal-positive L929
cells and were then titrated on Vero cell monolayers.
b
Titers shown are mean viral titers from duplicate tests.
c
– denotes that virus was not grown in that cell type.

Viruses were propagated in Vero cells (Chlorocebus sp. kidney cell line) or L929
cells (C3H mouse fibroblast cell line) and harvested at the peak of infection. Cell
debris was removed from culture fluid by centrifugation. Culture fluid from
virus-infected cells was titrated by plaque assay on Vero cell monolayers. The
concentration of virus (multiplicity of infection or MOI) used for infections in our
assays was based on titrations in Vero cells. Vero cells do not express αGal on
their surfaces, and viruses propagated in Vero cells do not carry αGal



carbohydrates on their envelopes. L929 cells express αGal on their surfaces, and
viruses grown in L929 cells have αGal incorporated into their envelopes (Welsh
et al, 1998). Vero and L929 cells were maintained as monolayers in MEM
supplemented with 10% FCS and 2.5% penicillin and streptomycin and 2.5% Lglutamine.

3.5 Time courses
For time courses of viral infections, GT-positive and GT-negative cells were
seeded in 6-well plastic plates and left to adhere anywhere from 4 and 24 h prior
to infection. The period of time cells were left to adhere to plates did not affect
the results of the time course infections. Before adding virus, media were
removed and replaced with 1mL of complete MEM. Virus was diluted to an MOI
from .01 to 1.0 in MEM, added to the cell monolayers, and left for adsorption
periods of 60 minutes for time courses. Culture fluid with unabsorbed virus was
removed, and the cells were washed twice and re-fed with 2mL MEM. Culture
fluid from infected cells was collected up to 72 hours post infection (h pi) and
titrated by plaque assay on Vero cell monolayers. Monolayers infected with GFP
viruses were observed using a Nikon Eclipse fluorescence microscope, and the
images were analyzed with NIS-Elements Advanced Research imaging software;
alternatively, cells were harvested by dispersion with trypsin and analyzed by
FACs analysis at each time point.





3.6 γMHV-68 time course and PCR analysis
Infections with γMHV-68 were completed on BL6 and BL6αGal cells, and virus
was quantified by PCR. Cells were seeded in 6-well plastic plates and left to
adhere for 24 h prior to infection. Before adding virus, media was removed and
replaced with 1mL of complete MEM. Virus was diluted to an MOI of 1.0 in
media, added to the cell monolayers, and left for adsorption periods of 60
minutes. Culture fluid with unabsorbed virus was removed, and cells were
washed twice and re-fed with 2mL MEM. Cells were harvested at 24, 48 or 62 h
pi, counted, and then prepped for PCR analysis using the CFX detection system
(BioRad Laboratories, Hercules, CA). The two amplification primers for the viral
ORF49 were as follows: forward primer, 5'-CCTGGCCATGGTTACATACTC-3;
reverse primer, 5'-GGAACATAATCCATAAGCAGGGT-3' (Lee et al., 2007).
No calibration standard was readily available for use, so quantification of viral
copy number (absolute quantification) was not possible. Instead, samples were
normalized using a reference gene, the housekeeping gene β-actin, found in host
cells, to control for relative differences in spleen size. DNA synthesis was
monitored using the nucleic acid stain SYBR Green I. Samples of γMHV-68
from culture fluid and water were used as positive and negative controls,
respectively. PCR conditions were as follows: 95°C for 10 mins denaturation,
and 95°C for 30 s, 62°C for 30 s and 72°C for 30 s, for 37 cycles. Samples were
tested in duplicate. The quantification cycle or Cq (the number of cycles where
the fluorescence increases above background) mean for the two values and for the
values of the housekeeping gene for each sample, were imported into the





QIAGEN RT2 profiler PCR array data analysis, version 3.5 website
(SABiosciences, a QIAGEN company)
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php), to obtain fold
change calculations. The sample with the lowest Cq mean was used to set the
baseline from which fold change calculations were derived. The measurement
unit “fold change” refers to a fold-difference in quantity of DNA of any sample
relative to the sample used as a baseline.

3.7 Infectious center assays and fluorescent-focus assays
Three different protocols were used for infectious center assays (ICA), and the
different techniques did not appear to influence final results. BL6 and BL6αGal
cells, at a concentration of 2x105 to 3x105 cells/well, were placed in tubes in 1 mL
MEM. Another 1 mL of diluted virus, either HSV-2 or SINV AR339, at an MOI
of 1.0, was then added the tube. The cell-virus suspension was left to incubate for
30, 60 or 90 minutes at 37° C, and tubes were shaken every 15 minutes. At the
end of each incubation point, virus was washed off twice by centrifugation with 3
mL media each time. At the end of each incubation period, cells were counted
and then plated over a Vero cell monolayer in serial dilution (analogous to a
plaque assay).

Otherwise, BL6 and BL6αGal cells, at a concentration 3x105 cells/well, were
plated in 12-well plates and left to adhere from 4 to 24 h. Media were removed
and virus was added in 500 μl at an MOI of 1.0 and left to incubate with cells for





30, 60 or 90 minutes at 37° C. Plates were shaken every 15 minutes. At the end
of each incubation period, cells were harvested by dispersion with trypsin and
washed twice by centrifugation. Cells were then counted and overlaid on Vero
cell monolayers in a serial dilution.

Alternately, BL6 and BL6αGal cells, at a concentration 3x105 cells/well, were
dispersed with trypsin and added to 96-well plates in 100 μl MEM. Virus was
then added to the wells in 100 μl and left to incubate for 30, 60 or 90 minutes at
37° C. Wells were gently pipetted every 15 minutes. At the end of each
incubation period, virus was washed off three times with 300 μl by centrifugation.
Cells were then counted and overlaid on Vero cell monolayers in a serial dilution.

For fluorescent focus-assays, BL6 and BL6αGal cells, at a concentration of 2x105
to 3x105 cells/well, were seeded in 6-well plastic plates and left to adhere from 4
to 24 h prior to infection. At time of infection, media were removed and replaced
with 1mL of complete MEM. Either TE12-GFP or HSV-1GFP virus was diluted
to an MOI from 0.01 to 1.0 in MEM, added to the cell monolayers, and left for
adsorption periods from 15 to 180 minutes for adsorption assays at 37° C.
Culture fluid with unabsorbed virus was removed, and cells were washed twice by
pipetting and were re-fed with 2mL MEM. The infection was left to run from 7 to
48 h. At the end of each time point, infected monolayers with GFP viruses were





observed using a Nikon Eclipse fluorescence microscope, and the images were
analyzed with NIS-Elements Advanced Research imaging software; alternatively,
cells were harvested by dispersion with trypsin and analyzed by FACs analysis.

3.8 Blocking assays
For blocking using the anti-Gal antibody, M86, 5x105 cells/well were seeded in 6well plates. Cells were left to adhere to plates from 5 to 24 h in 2 mL of MEM.
Media were removed and antibody was then added at different concentrations,
from 1:5 to 1:100, in 1 mL of MEM. Plates were left in the 37°C incubator for 60
minutes and then
SINV S.A.A.R86 or HSV-2, at an MOI of 0.1, in 100 μl MEM, was added to
cells. Cells were harvested using trypsin and washed by centrifugation, and then
were plated over Vero monolayers.

For blocking with liposomes (acquired from Dr. Uri Galili at the UMMS), 2x105
plaque-forming units (PFU) of SINV TE12-GFP virus in 50 μl media were added
to a solution of 1 μl or 2 μl of αGal-liposomes or control liposomes in a 50 μl
suspension (total volume of 100 μl). The virus-liposome mixtures were incubated
at 4° C for 1 h. The mixture was then added to 2x105 BL6 or BL6αGal cells
suspended in 100 μl of MEM. Cells were washed twice after a 2 h incubation
period by centrifugation and plated in 6-well plates. The infection was left for 9 h
and cells were harvested and analyzed by FACs. A second set of cells was left
plated for examination at a later time point.





3.9 Enzymatic removal of αGal from cell surfaces
To remove surface αGal from BL6αGal cells, 2x105 cells/well were added to 96well plates or to 2 mL tubes, in 100 μl of a phosphate buffered saline (PBS)
solution. BL6 were treated in parallel as controls. The PBS solution was adjusted
to pH ranging from 6.0 to 7.0. The enzyme is most efficient at pH 6.0, but cells
do not fare well for too long. At pH 7.0, the enzyme is less efficient and cells
(although seemingly more healthy in their environment) must be treated for an
extended period of time. The pH levels of 6.2 and 6.4 worked best for this assay.
The α-galactosidase from green coffee bean (Sigma-Aldrich) was added to cells at
varying concentrations, from 1:4 (25 μl) to 1:25 (4 μl), in a total of 100 μl PBS
solution. The enzyme is specific to αGal and cleaves off the terminal
disaccharide from glycoproteins and glycolipids on the cell surface. Cells were
incubated with enzyme for 60 min at 25°C or room temperature and shaken every
15 minutes. Cells were then washed twice by centrifugation. One set of cells was
tested directly after treatment for αGal expression using anti-Gal and analyzed by
FACs. SINV TE12-GFP virus was diluted to an MOI of 1.0 and added to the
second set of cells in 96-well plates or 2 mL tubes in 100 μl. Cells and virus were
incubated for 60 min and then were washed twice by centrifugation. Cells were
then seeded in 6-well plates and the infection was left from 6 to10 h. Cells were
then harvested and fixed for FACs analysis.





3.10 Disruption of the GT gene using RNAi
Four siRNA clones were purchased from QIAGEN (FlexiTube GeneSolution
GS14594 for Ggta1), each targeting a different region of the gene. siRNA clones
were tested individually, or in combination, to observe if any single one or
combination was especially effective in disrupting enzyme production. BL6αGal
cells were seeded in 12-well plates at concentrations of 2x104 cells/well to 6x104
cells/well. Each clone was tested at two concentrations, 5nM (0.3 μl) or 10nM
(0.6 μl) mixed with 4 μl transfection reagent in a total of 100 μl incomplete MEM
(no FCS or antibiotics). The mixture was slightly vortexed and let stand for
approximately 10 minutes for the reaction to occur. Next, 100 μl of each clone
mixture was added to freshly seeded cells (within 10 mins of seeding) in 500 μl
MEM. The mixture was added drop-style and distributed thoroughly throughout
each well. Cells were gently rocked and incubated in a 37° C incubator.
Cells were analyzed at various time points, from 20 to 66 h pi. As a control,
fluorescently labeled Cy3-siRNA was utilized to ensure the BL6αGal cells were
permissive of siRNA transfection.

3.11 Addition of αGal molecules to host cell membranes using FSL Galili
constructs
Vero cells, which do not express αGal, were used in these experiments as the
TE12-GFP virus replicates very well in this cell line. Cells at a concentration of
2x105 cells/well were added to 96-well plates, or 2 mL tubes, in 100 μl of neutral
PBS. FSL-Galili(tri) and control FSL-Biotin (Sigma-Aldrich) constructs are





composed of three fragments: a lipid, a spacer molecule and a functional
component. For these experiments, an αGal disaccharide or a Biotin molecule,
used as a control, constituted the functional component of the construct. These
constructs insert themselves into cell membranes via the lipid segment of the
construct and remain there for the lifetime of the cell. Either FSL-Galili(tri) or
FSL-Biotin at various concentrations, from 1:4 (25 μl) to 1:100 (1 μl), were added
to Vero cells in 100 μl PBS. The mixture was incubated from 60 -120 min and
then washed twice with PBS. One set of samples was used immediately after FSL
treatment, to test for αGal expression by anti-Gal binding and for Biotin
expression by fluorescently labeled streptavidin. SINV TE12-GFP virus at an
MOI of 1.0 in 100 μl of lipid-free media (incomplete MEM) was added to the
second set of samples, and samples were incubated for 60 min in the 37°
incubator. The virus was then washed off twice by centrifugation, and 6-well
plates were seeded with cells. Cells were harvested between 6-10 h pi and fixed
for FACs analysis.

3.12 HSV-2 infections in adult male mice and γ-irradiation
Male GT KO and C57BL/6J (WT B6) mice from 8 to 19 weeks of age were used
in various experiments where no γ-irradiation was administered. Mice were
inoculated intraperitoneally (i.p.) with 3.75x105 PFU or 5x105 PFU of HSV-2.
Infected mice were examined daily for physiological or behavioral changes and
sacrificed by cervical dislocation at 3, 4 and 5 days post infection. Fat pad, spleen
and liver were harvested and examined for signs of pathology, such as increase in





organ size or the formation of lesions. Virus from organ suspensions was titrated
by plaque assay on Vero cell monolayers. For in vivo HSV-2 infections with γirradiated animals, male GT KO and WT B6 mice between the ages of 8 and 14
weeks received 9-11Gy. Immediately after irradiation, mice were inoculated i.p.
with 3.75x104 PFU of HSV-2. Infected mice were observed and sacrificed as
described above at days 2, 3, 4, 5 and 6. Organs were harvested, examined, and
titrated as described previously.

3.12.1 HSV-2 infections of genetically crossed male mice
For irradiation experiments, WT- crossed (F1 x WT) and KO- crossed (F1 x KO)
male mice, aged approximately 12 weeks, were exposed to 10Gy of γ-irradiation,
and immediately after, were inoculated i.p. with 8.5x105 PFU of virus. Infected
mice were examined daily for physiological or behavioral changes and sacrificed
by cervical dislocation at day 6 pi. Livers were examined for pathology such as
lesions, and both liver and brain were homogenized for titration of virus. The
phenotype (αGal expresser or non-expresser) of genetically crossed mice was not
known; therefore, blood was taken at time of harvest via heart punctures, to
analyze for αGal expression of lymphocytes using BSl.

3.13 HSV-1 infections
For HSV-1 experiments, male and female GT KO, WT B6 and crossed mice (F1,
F1xKO) of 4 weeks of age were used. Mice were inoculated intranasally (i.n.)
with 1.8x104 PFU in 20 μl. Infected mice were sacrificed by cervical dislocation





at days 1, 2 and 4 pi. Lungs were harvested and virus from organ suspensions
was titrated by plaque assay on Vero cell monolayers. Blood was also taken by
performing heart punctures, and utilized to test for αGal expression by BS lectin
binding and analyzed by FACs.

3.14 γMHV-68 infections
Male and female KO, WT, F1 and F1xKO mice from 6-12 weeks of age were used
in various γMHV-68 experiments. Mice were inoculated i.p. with 3.5x103 PFU or
5.5x103 PFU of HSV-2. Because a productive infection lasts until about 10 dpi
(Sunil-Chandra et al., 1992), animals were sacrificed by inhalation of CO2 at days
4, 5, 7, 9 and 11 pi to observe the course of the infection. Spleens were harvested
and weighed at time of sacrifice and then prepped for molecular analysis. Viral
genomes were quantified with real-time PCR as described for in vitro
experiments.

3.15 SINV infections of adult mice and γ-irradiation
For SINV infections, male and female GT KO and WT B6 mice aged from 8 to 9
weeks were inoculated i.p. with 105 PFU of SINV S.A.AR86 in 200 μl MEM.
Blood, spleen, fat pads, or brain was harvested at days 1, 2, 3 and 5 for titration of
virus. Additionally, 8-week old mice were γ-irradiated with 10Gy and inoculated
with the same dose of virus. Blood, spleen, liver and fat pad were harvested at
day 6 pi.





3.16 SINV survival studies
GT KO and C57BL/6J suckling mice were infected via different routes and doses
of different SINV strains as follows: 1) 8-day old mice were inoculated intracranially (i.c.) with 200 PFU AR339 strain; 2) 13-day old mice were inoculated
subcutaneously (s.c.) with 1.68x103 PFU. Different inoculation routes and ages
were used to determine susceptibility to infection. Pregnant females were
monitored for day of birth, but because births from GT KO and WT B6 pups were
not synchronized to the day, infections of mice were staggered. Entire litters
(ranging from 3-8 pups) were infected when pups came of age, excluding runts.
Two to three litters per mouse strain were used for each experiment at each dose,
SINV strain, and age of infection. Mice were weighed daily and monitored for
symptoms of disease, including paralysis, lethargy and other possible signs of
neurological involvement such as spasms and shaking. Additionally, WT, KO,
F1xKO and F1xWT suckling mice aged 8 days were inoculated i.c. with 200 PFU
or 1.1x106 PFU of S.A.AR86 virus. Brains were harvested at day 1 and day 2 pi
for titration of virus.

3.17 Statistical methods
Survival data were analyzed by Log-rank (Mantel-Cox) test and Gehan-BreslowWilcoxon survival test using GraphPad inStat software. Analyses of individual
HSV-2 in vivo experiments were done using GraphPad inStat Student’s t tests and
chi-squares, and analyses of pooled experiments were completed using Minitab





Statistical software ANOVA mixed models with random assumption, factoring
dose, age, and experimental trial differences. Significance was set at P of ≤0.05; *
indicates a P of ≤0.05, ** a P of ≤0.005.





CHAPTER 4
DIFFERENTIAL HOST SUSCEPTIBILITY TO VIRUSES IN VITRO

4.1 Surface expression of αGal on experimental cell lines
Experiments were performed using paired cell lines. In each pair, one line
actively expressed the GT gene and the other did not. Figure 3a shows that the
BL6 cell line did not react with anti-Gal (left panel), or bind BS lectin (right
panel), which also reacts with αGal. The population of bright BL6 cells stained
with BSl (right shoulder of peak) may be due to the broader binding specificity of
BSl compared to anti-Gal. The BL6αGT line bound both anti-gal and BSl.
Figure 3b shows that the SK cell line did not react with anti-Gal, but SK-GT cells
bound it. The fluorescence peak from anti-Gal-stained SK-GT cell lines is broad,
indicating that there is variation in the quantity of αGal residues expressed on the
surface of individual cells within the GT-positive population. These data confirm
cell surface expression of αGal on BL6αGT and SK-GT at the time of these
experiments. This is an important issue, as continued passage of the cells can
result in decreased expression over time.





Figure 3: Expression of αGal on paired BL6 and SK cell lines. Cells were stained
with anti-Gal (IgM) or BS lectin (BSl-B4), both of which bind αGal. The light grey
peak represents αGal-negative cells and the black peak represents that of αGalpositive cells. BSl can bind αGal monomers, while anti-Gal requires multiple sites
for binding. MFI is mean fluorescence intensity of entire cell population. (A) BL6
and BL6αGT cell lines stained with anti-Gal or BSL. (B) SK and SK-GT stained
with anti-Gal.

4.2 Viral growth kinetics in the presence or absence of α1,3GT gene in the
host cell
If GT activity is important in the course of viral infections, then viral replication
should be contingent on whether or not host cells express GT. Previously,
preliminary work in the laboratory of Dr. Raymond Welsh had demonstrated
differential growth kinetics with Sindbis AR339, HSV-1 and HSV-2 in the paired
GT-modified human melanoma cell lines, the SK-N-MC pLXN (SK) (inactive
αGT gene) and SK-N-MC clone 10 (SK-GT) (active αGT gene). I also verified
GT-dependent differential susceptibility of SK and SK-GT cells to these viruses
during the course of this study. Sindbis viruses preferentially grew in GT-positive
cells whereas HSV-2 grew better in GT-negative cells (Table 2). Although the
SK and SK-GT cell lines had been similarly maintained and passaged, they had
slightly different morphologies and growth kinetics. SK cells consistently


established a uniform monolayer whereas SK-GT cells appeared to lose contact
inhibition after multiple passages. Because of this, it was important to verify
these findings in other paired cell lines.

TABLE 2: Replication of viruses in SK human melanoma cellsa

a

HSV and SINV viruses grown in either GT-positive or GT-negative SK cells were
titrated on Vero cell monolayers. These results were completed with single samples,
but are representative of between 2-4 experiments.
b
Titers shown were peak titers for that time course. MOI =1.0. Bolded numbers
indicate the comparably higher titer.

The majority of the research for this dissertation (including all in vitro
experiments that follow below) was completed using the paired B6 mouse-derived
melanoma cell lines, BL6 (GT-negative) and BL6αGT (GT-positive). In culture,
these cells were the most robust and were also the best matched in terms of
growth and phenotype. Various SINV strains, herpes viruses and other enveloped
viruses were screened on these cells to observe differences in susceptibility.
Table 3 shows representative data from infections on BL6 and BL6αGT
indicating that several of the viruses screened (VSV, LCMV, PV, MHV, MCMV)
grew equally well (as measured by titers from culture fluid) in both BL6 and
BL6αGT lines. Any variations in the growth of these viruses in the two cell lines
that did occur, such as with MCMV, were inconsistent.


TABLE 3: Replication of viruses in B6 melanoma cellsa

a

Viruses grown in either BL6 or BL6αGT cells were titrated on Vero cell
monolayers. Experiments were completed in duplicate and are representative of
between 2-4 tests.
b
Titers shown were peak titers for that time course. MOI for VSV and PV was 1.0
and 0.1 for LCMV and MHV.
c
- denotes no virus growth.

Differences in replication between cell lines were consistently observed for all
tested SINV strains (AR339, S.A.AR86, TR339, SVHR and TE12-GFP), HSV-1,
HSV-1 GFP and HSV-2. Notably, the SINV strains grew often to 10-20 fold
higher titers in the presence of αGT, whereas the HSV strains grew often to 100fold higher titers in the absence of αGT (Figure 4). SINV growth differences
between cell lines were observable early in the time course—after a single round
of viral replication (Figure 4b). SINV-infected BL6αGT monolayers also
exhibited more cytopathic effects (CPE) than BL6 cells. BL6 cell monolayers, in
contrast, were much more susceptible to HSV-1 and HSV-2 infections (Figure 4c)
and exhibited greater CPE. A third herpes virus, murine gammaherpes virus 68
(γMHV-68), also replicated better in GT-negative cells (Figure 4c).



Figure 4: Growth kinetics of SINV and herpes viruses in B16 cell lines. Results are
representative of >5 experiments for HSV and SINV and of 2 tests for γMHV-68.
Virus was diluted to an MOI of 1.0 in MEM, added in 100 μl (SINV strains) or 400μl
(herpes viruses) to the BL6 and BL6αGT monolayers, and left for an adsorption
period of 60 minutes. (A) and (C) During time courses, culture fluid from cell
monolayers were collected every 24 h for 72 h pi (SINV AR339 and γMHV-68) or
96 h pi (HSV 1 and 2). (B) For 12 h replication experiments, cell monolayers were
infected with SINV viruses at an MOI of 0.1 and culture fluid was collected, starting
at 12 h pi.

To further test differential replication of γMHV-68 in the two cell types, time
courses were completed using the BL6 and BL6αGal paired cell lines. At various
time points post infection, cell populations were harvested and DNA from cell
populations was analyzed by real-time PCR. Absolute quantification of viral



copy number was not possible because no calibration standard was used. Instead,
relative quantity of DNA was standardized using a housekeeping gene, as
discussed in Methods and Materials. For each experiment, the sample with the
lowest quantity of viral DNA was set as a baseline to compare the rest of the
samples to. The unit of measurement, “fold change”, refers to a fold difference in
quantity of DNA of each sample to the quantity of the baseline sample. At 24 h
pi, the quantity of viral DNA in GT-negative cells was three times that of GTpositive cells, and this difference was increased to almost 13-fold by 68 h pi
(Figure 5, left graph). It is of interest that there was the same relative amount of
viral DNA present at 24 h and at 68 h pi in the infected BL6αGal cell population.
In a separate experiment, at 48 h pi, there was approximately 1.8 times more viral
DNA in the population of BL6 cells relative to the BL6αGal cells (Figure 5, right
graph). The relatively greater quantity of DNA found in GT-negative cells
compared to GT-positive cells correlates with higher viral titers found in culture
fluid from infected BL6 and BL6αGal cell populations.





Figure 5: Relative viral quantity in infected BL6 and BL6αGal. Results are
representative of two separate experiments completed in duplicate. Time courses
were completed as previously described and infected cells were harvested for
analysis at 24 and 68 h pi, or at 48 h pi. Virus was used at an MOI of 1.0. Viral
DNA was quantified using real-time PCR.

In the systems studied here, related viruses behaved similarly during infections of
each cell type. Viral preference for expression or non-expression of αGT in host
cells appears to be a general characteristic of certain viruses, and also appears to
be virus-dependent but not viral-strain dependent.

4.3 Viral expression of αGal does not affect host-cell susceptibility to SINV
and HSV strains
Enveloped viruses incorporate host-cell carbohydrates onto their envelopes during
egress from cells, and this in turn can affect interactions with subsequent host
cells. Various enveloped viruses, including SINV, acquire αGal after passages in
mouse fibroblast L929 (αGT-positive) cells (Repik et al., 1994; Welsh et al.,
1998). To determine whether viral infectivity on our two cell lines was affected
by the presence of αGal on the virion, time course assays were completed on BL6


and BL6αGT cell lines with HSV-1 and 2 and with several SINV strains that had
been propagated in L929 cells (designated SINVαgal, HSV-1αgal and HSV2αgal). These SINVαGal virus strains still preferentially replicated in cells
positive for αGT gene expression (Figure 6a), while HSV-1αgal and HSV-2αgal
both preferentially grew in αGT-negative cells (Figure 6b).

Figure 6: Growth kinetics of αGal expressing viruses in BL6 cell lines. Results are
representative of 2 separate experiments.
SINV and herpes viruses were
propagated in αGal-positive L929 cells to produce virions expressing αGal. Time
courses were completed as previously described. SINV(αgal) was used at an MOI of
0.1 and or HSV(αgal) at an MOI of 0.01. Culture fluid was harvested every 12 h for
48 hpi (SINV(αgal)) or every 24 h for 72 h pi (HSV(αgal)).



Further, the αGal-expressing SINV S.A.AR86 virus replicated to similar levels to
non-αGal expressing virus when used at the same MOI (Table 4). These results
indicate that host-cell susceptibility to various SINV strains and to HSV 1 and 2 is
affected by host-cell differences in αGT gene expression but not by variable αGal
expression on the viruses.

TABLE 4: Replication of S.A.AR86 and S.A.AR86(αgal) in BL6 cellsa

a

BL6 and BL6αGT were infected with SINV S.A.AR86 expressing or not expressing
αGal on its envelope at an MOI of 0.1. Experiment was done in duplicate. Results
are representative of a single experiment, and titers are consistent with results from
other time courses with S.A.AR86 at similar MOI.
b
The titers shown are peak titers during a 48 h time course. Higher titers are
bolded.

4.4 Level of viral replication correlates with the proportion of infected cells
in the population
Susceptibility to viral infections that is dependent on αGT-expression should be a
general characteristic of the entire cell population. High viral titers as measured
from culture fluid, however, could indicate two different phenomena: 1) many
infected cells producing moderate levels of virus or 2) a subpopulation of infected
cells producing high amounts of virus. In order to investigate whether the
amounts of virus in culture fluid correlated with the fraction of infected cells in
the population, we used SINV and HSV-1 recombinants that express a green



fluorescent protein (SINV TE12-GFP and HSV-1 GFP ICP8 mutant) during
replication, and we performed time course assays on BL6 and BL6αGT cells.
HSV-1 GFP has reduced replication potential due to an ICP8 gene mutation that
interferes with late gene expression, but not with its ability to initiate infection;
therefore, differences in virus yields between cell types can still indicate a
difference in cell susceptibility to infection. Further, GFP is expressed as a
delayed early gene product, and so fluorescence in host cells is a useful measure
of a first round of infection. Infected cells were directly measured via FACs, and
virus from culture fluid was quantified by plaque assay. As seen with wild type
strains, SINV TE12-GFP replicated better in BL6αGT cells (Figure 7a), whereas
HSV-1 GFP replicated better in BL6 cells (Figure 7b). Under fluorescence
microscopy, GFP SINV- infected BL6αGT cell monolayers had relatively large
areas of fluorescing cells compared to SINV-infected αGT-negative cells (Figure
7c). Conversely, HSV-1-infected αGT-positive cell monolayers exhibited
relatively small foci of fluorescing cells compared to HSV-1-infected BL6 cells
(Figure 7d). Time course studies using FACs analysis showed that a substantially
greater fraction of SINV-infected GT-positive cells expressed GFP (Figure 7e),
compared to a small subpopulation of BL6 cells, even after multiple rounds of
replication. In contrast, a much greater proportion of HSV-1-infected BL6 cells
expressed GFP, and only a small fraction of αGT-positive cells were GFP positive
for the duration of the time course (Figure 7f). Comparable mean fluorescent
intensity (MFI) levels of GFP were observed across both cell lines during SINV
and HSV infections (Figures 7g and 7h), suggesting that once cells are





productively infected, virus is synthesized at similar levels in both cell lines.
These data suggest that differences in viral replication between host cell types are
due to differential success in virus establishing a productive infection.







Figure 7: Replication of GFP viruses in BL6 cell lines. Time courses on BL6 and
BL6αGT cells were performed as previously described. Results with SINV GFP are
representative of >5 experiments and for 3 experiments with HSV GFP. SINV
TE12-GFP was used at an MOI of 1 and HSV-1 GFP at an MOI of .1. (A) Culture
fluid was collected from SINV-infected monolayers for titration every 6 h for 26 h pi
or (B) from HSV-infected monolayers every 12 h for 48 h pi. (C) and (D) Infected
monolayers were observed under a fluorescence microscope to visually monitor
infection and (E) and (F) cells were harvested for FACs analysis. (G) and (H) Mean
fluorescence intensity of GFP expressing cells was measured via FACs Diva
Software.



4.5 Differences in host-cell susceptibility are evident early after viral
infection
Using GFP viruses, the success of an initial infection in host cells can be
measured by FACs analysis, as infected cells will fluoresce. Cells were incubated
with either SIN GFP or HSV-1 GFP for varying time periods, and infected cells
were harvested prior to completion of a first round of replication—thus measuring
initial infection levels—and analyzed via FACs. In HSV-1 GFP assays longer
adsorption time resulted in a small increase of infected BL6 cells, but the
infection on BL6αGT monolayers was almost negligible (Figure 8a). In SINV
GFP assays, longer adsorption time resulted in higher fractions of αGT-positive
infected cells, but not of αGT-negative cells; infection levels in BL6 cell
populations did not increase with adsorption times longer than 120 minutes
(Figure 8b). Additionally, it is of interest that following multiple rounds of
replication (Figure 8c) the proportion of GFP SINV-infected cells in the BL6
population declined. This was not a result of lysed cell monolayers, as at 36 h pi
the BL6 cells appeared more intact than BL6αGT cell monolayers (Figure 8d) and
only focal areas exhibited cytopathic effects; the majority of the monolayer
simply appeared to resist infection. This could suggest heterogenicity of the BL6
cell population with respect to permissivity to SINV infection, whereby some
cells are permissive to infection and others are not. This could also indicate that
viral infectivity declines after a first round of replication, a possible consequence
of defective interfering (DI) particles. Along with infectious particles, Sindbis
virus can generate DI particles that disrupt the replication cycle (Shenk and





Stollar, 1973). However, low MOIs were often used for SINV infection assays to
reduce the possibility of this occurrence. Additionally, reduced infectivity was
not a result of multiple rounds of infection, but was noticeable during the initial
infection. This could suggest that DI particles are present in the viral stock, yet
interfererence did not appear to be an issue for infections on Vero or BL6αGT
cells. In either case, the mechanism by which infection is limited in BL6 cells
appears to occur early in virus-host cell interactions.





Figure 8: Virus adsorption to BL6 and BL6αGT cell lines. Results are
representative of >5 experiments with SINV GFP and 3 for HSV GFP. Virus was
diluted to an MOI of 1.0 (SINV TE12-GFP) or MOI of 0.1 (GFP HSV-1) in MEM,
and added in 100 μl to the BL6 and BL6αGT monolayers for varying periods of
time. Culture fluid with unabsorbed virus was removed after each incubation end
point, and cells were washed twice with media and re-fed with 2 mL MEM. At
harvest, cells were prepared for FACS analysis. (A) GFP HSV-1 was incubated with
cells for 30, 60 or 90 minutes and monolayers were harvested at 18 h pi, prior to one
round of replication. (B) GFP SINV was incubated with cells between 15 to 180
minutes and cells were harvested between 7 to 10 h pi, prior to one round of
replication. (C) GFP SINV was incubated with cells for 60, 120 or 180 minutes and
cells were harvested at 35 h pi, after multiple rounds of infection. (D) GFP SINV
infected cell monolayers approximately 36 h pi under light microscopy.

4.6 Testing restriction of SINV infection by blocking αGal sites on host cells
Fluorescence focus-assays indicate that differences in viral growth correlate with
the successful infection of a host cell. Host-cell glycans are commonly utilized by
viruses during the entry process; as such, the α-galactosyltransferase product αGal
could play a role in facilitating or restricting infection. To explore the possible



role of αGal in viral entry, αGal sites were blocked using the anti-Gal antibody
(ab), M86. BL6 and BL6αGal cell monolayers were treated with the M86 ab at
varying dilutions and were then inoculated with the SINV S.A.AR86 strain, which
has shown preference for preferentially replicating in αGal positive cells. In cell
cultures without ab treatment, SINV preferentially replicates in cells expressing
αGal (Figure 9). For BL6 cell populations, the relative fraction of infected cells
does not change whether it is untreated or treated with M86. In contrast, the
fraction of infected BL6αGal cells treated with 1:10 dilution of anti-Gal is slightly
reduced (Figure 9, left graph). In a second experiment (Figure 9, right graph), the
fraction of BL6αGal cells treated with 1:50 dilution of M86 drops significantly
compared to the untreated, SINV-infected cells. When the concentration of antiGal treatment is reduced, the fraction of infected BL6αGal cells increases, but is
still lower relative to the fraction of untreated, SINV-infected cells (Figure 9, right
graph). These data must be interpreted with caution, however, for two reasons: 1)
the standard deviation for experimental values completed in duplicate is large,
which indicates a large margin of error and 2) additional experiments to confirm
these observations were not successful. In several experiments, the antibody
agglutinated cells in monolayers, or in suspension, during the incubation period
and experiments were terminated. Overall, although some results may indicate
that blocking αGal sites restricts SINV infection (at least with the S.A.AR86
strain), the data are not sufficiently reliable to confirm this phenomenon.





Figure 9: Blocking host cell αGal sites with anti-Gal. Anti-Gal antibody was used to
bind to αGal sites on BL6 and BL6αGal monolayers. Antibody was added to cell
monolayer at various dilutions and left for 60 min, then washed off. Virus was then
added at an MOI of 0.1 and left for 60 min. Cells were removed by dispersion with
trypsin and plated over Vero monolayers in serial dilution.

Additional methods to block glycan-virus interactions were attempted, including
using free αGal in solution acquired from Dr. Uri Galili at the UMMS. The αGal
solution was incubated with SINV AR339 and then the αGal-virus solution was
added to BL6 and BL6αGal monolayers. The rationale was that if SINV binds
αGal residues on host cells, then it may also bind free αGal molecules in solution,
which would then prevent binding to the host cell. Unfortunately, the cell
monolayers were damaged by the treatment, so this strategy was not effective.

A third blocking method was the use of liposomes that contained αGal epitopes in
the membrane and control liposomes derived from KO pig red blood cells (both
acquired from Dr. Uri Galili). Liposomes were incubated with virus, and the



liposome-virus solution was added to BL6 and BL6αGal monolayers. The
function of αGal liposomes in these experiments was analogues to free αGal in
solution described above. However, the cells reacted poorly to the treatment
(Figure 10). Similarly to anti-Gal treatment, the liposomes tended to agglutinate
the cells in culture. At 9 h pi, cells from some wells were harvested and fixed for
FACs analysis, and cells from other wells were left for later examination. After
24 h post-treatment, the cell monolayers began to recover and returned to their
normal morphology. Despite this, due to the unhealthy morphology of cells
directly after treatment, experiments were terminated.

Figure 10: αGal liposome treatment of BL6 and BL6αGal cells. Monolayers at 2 h
post-treatment with the liposome.

4.7 Enzymatic removal of αGal from host cells
Results from blocking experiments were inconclusive due to problems with
replicating results or with reagents that were toxic to cells. However, the role of
αGal in viral infections could still be examined by removal of the sugar from the
surface of host cells. BL6 and BL6αGal cells were treated with the green bean αgalactosidase enzyme that cleaves the terminal Gal residue on the cell’s surface.


Under the right conditions (discussed in methods), the enzyme was very efficient
at removing surface αGal from cells without damaging cells (Figure 11), and αGal
residues were not detected on BL6αGal cells at normal levels by 6 h post
treatment. The unusually high MFI for the negligible αGal-positive population in
the BL6 sample was possibly due to non-specific binding.

Figure 11: Enzymatic treatment of BL6 and BL6αGal cells. Cells were treated with
5 μl of enzyme in 100 μl of pbs at pH 6.2 for 45 minutes. Cells were stained for αGal
expression using the anti-gal ab M86. MFI is mean fluorescence intensity of entire
cell population.



Once the removal of αGal residues was confirmed via FACs analysis, cells were
infected with SINV TE12-GFP. Infections were left between 6-10 h, and infected
cells were harvested prior to a first round of replication—thus measuring initial
infection levels—and analyzed via FACs. As expected, a greater proportion of
the BL6αGal cell population was infected with SINV compared to BL6 cells
(Figure 12a, left column). Green bean α-galactosidase is most efficient at low pH
(6.0-7.0). To control for any effects of the harsh conditions on cells, infections
were performed in both normal cell culture media and also in low pH solution.
Incubation of cells in either low pH solution or MEM did not appear to affect
susceptibility to infection for either cell type (Figure 12a, right column). Removal
of αGal from BL6αGal cells increased the proportion of cells infected by SINV
TE12-GFP (Figure 12b, top panel). In various experiments, infection levels
ranged between 2 to 6-fold lower in treated cells compared to untreated cells.
Surprisingly, treatment with α-galactosidase also resulted in reduced levels of
infection for BL6 cells compared to untreated cells (Figure 12b, bottom panel).
The reduced infection observed in BL6 cells could indicate that α-galactosidase
also interacts with another component on the cells that is involved in
susceptibility to SIN infection. Overall, treatment of cells with the galactosidase
did not identify a role for αGal in viral infections. More work is needed to
understand the dynamics of αGal cleavage in BL6 cells and SINV infection.





Figure 12: Infection of enzymatically treated cells with SINV TE12-GFP. Bl6 and
BL6αGal cells were treated with 5 μl of α-galactosidase in 100 μl of PBS at pH 6.2
for 45 minutes. Cells were then infected with virus at an MOI of 1.0 and infection
ran for 7 h. As a control, cells were infected in MEM media and also in low pH
solution. Cells were harvested by dispersion using trypsin and analyzed by FACs.
MFI is mean fluorescence intensity of GFP-positive cells.

These experiments also showed that the MFI of infected BL6 cells is considerably
higher than infected BL6αGal cells (Figure12b). This phenomenon was not
observed in experiments completed with the first lot of virus propagated in Vero
cells, but was noticed after several passages (approximately 3) in Vero cells
where viral stocks were grown. MFI is used as a relative measure of viral
replication within a cell; brighter cells have more viral replication and thus
express greater amounts of GFP. For BL6 cells, that could suggest that although
few cells become infected in the population, the virus replicates very well once



inside the cell. The relatively lower viral output, measured from culture fluid,
could result from the initial low-level infection in the population or could indicate
that viral egress is restricted in the infected cell subpopulation.

It was also possible that the two cell types had different IFN-induced antiviral
activity, and therefore responded to viral infection differently. Sindbis virus is
sensitive to antiviral effects of IFN α/β. The virus replicated well in the BL6
cells, but infection levels were low compared to BL6αGal. If BL6 cells produced
greater amounts of IFN early during infection, it could have protected the rest of
the population from becoming infected, and thus explain the greater proportion of
infected BL6αGal cells. An inhibition assay for interferon was performed in
order to measure IFN in culture fluid of SINV TE12-GFP infected BL6 and
BL6αGal cells. In some assays, both cell lines had comparable levels of IFN
(Figure 13, left graph) but in other assays, the BL6αGal cell population produced
more IFN than the BL6 population (Figure 13, right graph). It is possible that
higher levels of viral replication in the BL6αGal cell population induced higher
levels of interferon production. It is clear, however, that the lower proportion of
infected cells in the BL6 population was not a result of a relatively more robust
IFN response.





Figure 13: Assay for interferon production in the BL6 and BL6αGal cell lines. Cells
were infected with SINV TE12-GFP and culture fluid was harvested from infected
cells from 6 to 36 h pi. Virus in samples of culture fluid was then inactivated under
UV light to be used in the VSV protection assay.

4.8 Addition of αGal terminal residues to GT-negative host cells
Attempts to understand the role of αGal in viral-host interactions by blocking or
removal of the surface sugar or knockdown of GT activity were not successful.
An alternative method was to add the carbohydrate molecule to GT-deficient host
cells and examine its effects on viral infections. The FSL (function, spacer, lipid)
construct system was a good candidate for these experiments because the
constructs are composed of three parts: a functional terminal end, a spacer
molecule and a lipid molecule. The lipid portion can insert itself into membranes
(be it cellular or viral) and the functional portion is exposed in the extracellular
space. The functional unit of the FSL-Galili(tri) construct contains the
Galα1,3Galβ1,4GalCNAc molecule. The BL6 cell line seemed a good candidate
for these experiments, but these cells were not very receptive to the FSL
constructs. A relatively high quantity of the reagent was necessary to produce



only a small proportion of αGal-expressing cells in the population. Instead, Vero
cells that derive from Chlorocebus sp. and do not have a functional GT gene,
were utilized. Cells were treated with the FSL-Galili(tri) to express αGal residues
on the surface. Figure 14a shows that a vast majority of Vero cells was made to
express αGal, although at relatively low levels. Treated and untreated Vero cells
were then used to examine viral-host cell glycan interactions as both cell types
were identical, but for the expression of terminal αGal. Because the addition of
an exogenous molecule to the host cell might have unforeseen effects that can
skew findings, a control FSL construct was used: the FSL-Biotin, which has a
Biotin molecule as the functional portion of the construct. The control construct
also integrates itself well into the cell membrane (Figure 14b).

Figure 14: FSL treatment of Vero cells for SINV TE12-GFP infection. Cells were
incubated with either FSL Galili(tri) or control FSL-Biotin at a concentration of 1:4
for 60 min and then infected with virus at an MOI of 1.0. At 2.5 h post treatment,
cells were tested for expression of αGal or Biotin using FACs. (A) Cells treated with
FSL-Galili(tri) were tested for successful insertion using anti-Gal, M86 and (B) Cells
treated with FSL-Biotin were tested for successful insertion using fluorescently
labeled streptavidin. MFI is mean fluorescence intensity of entire cell population.



Vero cells treated with both constructs were infected with the GFP SINV TE12
strain and cells were harvested prior to a second round of replication to look at the
initial infection cycle. Compared to untreated Vero cells infected with the virus
(Figure 15a), the proportion of FSL-Galili(tri) treated cells that became infected
increased slightly, and the proportion of FSL-Biotin treated cells that became
infected dropped slightly (Figure 15b). Strangely, when the concentration of FSL
constructs is reduced (resulting in fewer constructs inserted into the host cell
membrane), the infection level of FSL-Galili(tri) treated cells is slightly reduced,
but infection level of FSL-Biotin treated cells is increased (Figure 15c). Other
experiments demonstrated this same phenomenon. Cells treated with higher
concentrations of FSL-Galili(tri) resulted in more significant increases in TE12GFP infection; but cell treatment with low concentrations of FSL-Biotin also
resulted in an increase in TE12-GFP infected cells. These data suggest that the
constructs do have a moderate effect in viral-host cell interaction; however, it is
not specific to αGal residues.





Figure 15: Infection of FSL-treated Vero cells with SINV TE12-GFP. Cells were
incubated with either FSL Galili(tri) or control FSL-Biotin and were infected with
TE12-GFP at an MOI of 1.0. (A) Control: virus infected cells without FSL
treatment. (B) Cells treated with FSL-Galili(tri) or FSL-Biotin at a concentration of
1:4 and infected with virus. (C) Cells treated FSL-Galili(tri) or FSL-Biotin at a
concentration of 1:10 and infected with virus.

To examine if FSL-constructs affected the course of other viral infections, Vero
cells treated with the constructs were infected with HSV-1 GFP. Due to low
quantity of available reagent, cells were treated with a more dilute mixture, and
accordingly, a decrease in αGal expression on treated cells was observed (Figure
16a). Infected cells were harvested prior to a second round of replication in order
to observe an initial infection cycle. No difference was observed in the level of
infection between treated and untreated Vero cells, although it is possible results
were skewed by reduced αGal expression on treated cells (Figure 16b). However,
repeats of this experiment resulted in a greater proportion of cells incorporating



αGal molecules, but differences in infection levels between treated and untreated
cells were still not observed. Overall, addition of αGal to GT-deficient host cells
did not identify a role for αGal in viral infections.

Figure 16: FSL treatment of Vero cells for HSV-1 GFP infection. Cells were
incubated with either FSL Galili(tri) of 1:10 for 60 min and then infected with
HSV-1 GFP at an MOI of 0.2. (A) At 2 h post treatment, cells were tested for
expression of αGal using anti-Gal, M86. MFI is mean fluorescent intensity of entire
cell population (B) Cells were harvested 20 hpi and analyzed by FACs for GFP
expression.

In vitro experiments showed that the presence or absence of the GT gene in a host
cell plays an important role in the course of viral infections. The viral kinetics of
various herpes viruses and Sindbis virus strains seem to be dependent on the state
of GT expression in the host. Herpes viruses preferentially replicate and infect
GT-negative host cells, and SINV strains have greater infectivity in GT-positive
cells. Host cell susceptibility to infection appears to be determined by an event
early in virus-cell interaction. Enzymatic removal of αGal from cell surfaces may
indicate that the presence of αGal plays a role in facilitating infection by SINV;
however, the mechanism by which susceptibility is affected could not be
established.


CHAPTER 5
DIFFERENTIAL HOST SUSCEPTIBILITY TO VIRUSES IN VIVO

5.1 T KO mice are more susceptible than WT mice to HSV-2 infections
The role of the GT gene or αGal expression must be relevant in vivo in order to
have implications for primate evolution. To test whether our in vitro data could
be corroborated in vivo, we used C57BL/6J (WT B6) mice that naturally express
the GT gene and GT knockout mice (GT KO) that lack it. Mice aged 8 to 19
weeks were inoculated by the intraperitoneal route with different doses of HSV-2.
From i.p. inoculations, HSV-2, which is not highly pathogenic in B6 mice,
spreads via blood to visceral organs. Spleen, liver and visceral fat pads proximal
to the injection site were harvested at various days post infection to quantify virus.
At day 3 pi, viral loads from splenic suspensions were often higher in KO mice
compared to the WT, but this was not always statistically significant. However,
virus accumulated significantly more in livers of GT KO mice compared to livers
of age-matched WT B6 mice, regardless of initial inoculum. Virus was detected
in a greater proportion of KO mice (83.4%) compared to WT mice (45.5%) (x2=
5.9, df = 1, P < 0.02), and macroscopic hepatic lesions commonly associated with
HSV-2 infections following i.p. inoculation (Mogesen et al., 1974; Mogesen,
1977) were more frequently observed in KO mice (27.7%) than in WT mice
(5.5%). Independent experiments did not always show statistically significant
differences in liver viral load between the two mouse types, but analysis of
variance (ANOVA) of titers from pooled experiments demonstrated significant





differences (F=8.36; df=1; p=.007). Additionally, by day 4 pi, virus was detected
in a significantly greater proportion of livers from KO mice (88.2%) than WT
mice (35.3%) (x2 = 10.09, df = 1, P < 0.002). Viral load was also significantly
higher in KO mice compared to WT mice, irrespective of age of mouse or viral
dose administered (Figure 17a and b), and a greater proportion of KO mice
exhibited hepatic necrosis (29.4%) compared to WT mice (11.8%). By day 5
post-infection, KO and WT mice had largely cleared the infection from all organs
tested. These data show differences in resistance to HSV-2 between KO and WT
mice, reflected in the amount of virus isolated from liver and from the level of
hepatic necrosis observed.

Figure 17: HSV-2 infections of KO and WT B6 mice. Mice were inoculated i.p. with
HSV-2. Organs for titration (PFU/organ) from mice were harvested at days 3,4 and
5. In figure, wo = weeks old. (A) Mice aged 8-weeks of age were inoculated with
5x105 PFU in 400μl media or (B) of 9, 11 or 19 weeks of age were inoculated with
3.75x105 PFU in 300μl media.



The GT KO and WT B6 mouse lines, although genetically similar, could present
differences in their immue response to infection. To ensure that observed
differences in susceptibility to HSV-2 were not an artiface of immune system
differences between the two mouse lines, mice were given a high dose of gammairradiation directly prior to infection. Replication of HSV-2 was considerably
enhanced in the spleen and livers of these immunocompromised KO mice but
only slightly improved in WT mice. At day 2, the virus was barely detectable in
spleens of WT mice, but KO mice had mean viral titers up to 80-fold higher
(Figure 18, left panel). By day 5 post-infection, all KO mice exhibited numerous
large focal necrotic lesions and elevated viral load in livers (Figure 18, right
panel). In contrast, only a few WT mice presented small hepatic lesions and
relatively lower (or undetectable) viral titers. Thus, the presence of GT confers a
level of resistance to HSV-2 infection in mice.





Figure 18: HSV-2 infections of γ-irradiated mice. Mice were aged 8 to 14 weeks were
inoculated with 3.75x105 PFU of HSV-2 in 300 μl media. Organs for titration
(PFU/organ) were harvested at days 2,3,4,5 or 6. In figure, wo = weeks old.

5.2 Genetic background of GT KO mice and susceptibility to HSV-2
GT KO mice were created in a DBA/2, 129Sv and B6 background. Despite being
backcrossed into the C57BL/6J background over multiple generations, it is
important to ensure that any genotypic differences between KO and WT mice do
not influence response to HSV-2 infection. In preliminary tests to determine this,
WT, KO and various mouse crosses (F1, F1xWT, F1xF1, F1xKO) of varying ages
were γ-irradiated with 10Gy and immediately infected with HSV-2. αGal
expression was tested from peripheral blood samples using anti-Gal antibody. By
BS lectin binding, expression of αGal in the cell population of GT KO mice is
close to zero, while in WT B6 mice, it can range between 80-95% (Figure 19). It
should be noted that in the heterogeneous population derived from blood of WT
B6 mice, there was no distinct separation between the population of expressers



and of non-expressers. As in other tissues, αGal-expression likely occurs across a
spectrum whereby different individual cells express different quantities of αGal
on the surface.

Figure 19: Expression of αGal on lymphocytes of KO and WT mice. Cells were
stained with BS lectin (BSl-B4), which binds αGal monomers. (Left panel) Cell
populations derived from KO mice express practically no αGal on their surface,
while (right panel) the majority of cells in the population derived from WT mice
express different quantities of surface αGal. MFI is mean fluorescence intensity of
entire cell population.

To analyze the role of the GT KO genetic background in its susceptibility to
HSV-2, age-matched F1 male mice that had been backcrossed with parental
strains (F1xWT or F1xKO) were γ-irradiated with 10Gy and then infected i.p. with
HSV-2. Blood was collected and utilized for testing αGal expression with BS
lectin. Additional antibodies were included in fluorescence analysis to locate a
homogenous population of lymphocytes, and limit factors that could influence the
analysis (e.g., different cell types expressing different levels of αGal). The
congenic marker, Thy 1.2, revealed that there were very few lymphocytes in
peripheral blood preps, potentially because gamma radiation had eliminated much



of the population. Using the small Thy 1.2 subpopulation, individuals with very
low αGal expression vs. high αGal expression were differentiated (Figure 20a).
At day 6 pi, there were no statistically significant differences in mean viral titers
from liver or brain suspensions of αGal-negative and αGal-positive individuals
(Figure 20b). The three αGal-negative mice with the highest viral load exhibited
macroscopic hepatic lesions. One αGal-positive mouse had light spotting on the
liver but the corresponding viral titer was below the limit of detection. Additional
experiments with crossed mice were completed with a modified protocol,
whereby blood was taken a week prior to infections to determine αGal status of
the animal, as gamma-irradiation depleted the immune cell population used for
αGal detection. Unfortunately, in three separate experiments, KO and WT mice
did not yield sufficiently high viral titers for proper analysis, even after viral
inoculum was increased. Although these results trend in the direction of previous
findings which showed that KO mice developed greater pathology compared to
WT mice, the observed differences in this experiment were not statistically
significant. Overall, these do not clarify whether the GT KO background plays a
role in its increased susceptibility to HSV-2 infections.





Figure 20: HSV-2 infection of backcrossed male mice. Mice of genetically crossed
background, aged 12 weeks, were γ-irradiated and subsequently inoculated i.p. with
8.5x105 PFU in 100μl media. (A) αGal expression of lymphocytes from blood preps
was tested using BSl. (B) Liver and brain were harvested at day 6 pi.  denotes
large hepatic lesions.

5.3 WT and GT KO mice are similarly susceptible to HSV-1 infections
In vitro, herpes simplex type 1 exhibited preferential growth in cells that lacked
GT activity. WT B6 mice are highly resistant to HSV-1 infection via the i.p.
route, but are susceptible if infected intranasally (i.n.) and quickly develop
pneumonia (Adler et al., 1997). In order to verify if in vitro findings translate to
an in vivo system, males aged 4 weeks, were anesthetized and infected i.n. with
1.8x104 PFU. Numerous crossed mice were readily available for testing and were
used in these experiments. BS lectin was used to test for αGal expression in
peripheral lymphocytes. At day 1 and day 2 pi, there was no difference in mean
viral titer from suspensions of whole lung between αGal-negative and αGalpositive individuals (Figure 21). By day 4 pi, both groups of mice appeared to be
clearing the virus from lungs. These results suggest KO mice do not have
increased susceptibility to HSV-1 infections via the intra-nasal route, compared to
their αGal-expressing counterparts.


Figure 21: HSV-1 infections of WT, KO and crossed male mice. Mice, aged 4 weeks,
were inoculated i.n. with 1.8x104 PFU in 20 μl. Lungs were harvested at days 1, 2
and 4. Day 1 results are representative of pooled data from two separate
experiments performed under the same parameters using KO, F1 and F1xKO mice.
Day two experiments were conducted on F1xKO mice. Day 4 experiments were
conducted on KO and WT. Blood was taken at time of sacrifice to verify αGal
expression.

5.4 WT B6 and GT KO infections with γMHV-68
Similar to the herpes viruses tested previously, the gammaherpes virus, γMHV-68
replicated to higher levels in cells negative for GT expression. In order to test for
possible GT-dependent differences in susceptibility to infection in vivo, GT KO
and WT B6 male mice aged 8-9 weeks, were inoculated i.p. with virus, and
spleens were harvested at day 7 pi. Titers from splenic suspensions (PFU/organ)
were too low, or under the limit of detection, to be analyzed by plaque assay.
However, in mice, after virus is cleared from circulation (acute infection), γMHV68 establishes a latent infection in B cells of the spleen that can result in
splenomegaly (Sunil-Chandra et al., 1992). By macroscopic examination,
relatively larger spleens were observed from GT KO mice compared to spleens
from WT mice at 7 days pi (Figure 22).



Figure 22: γMHV-68 infection on KO and WT mice. Mice aged 9 weeks were
inoculated i.p. with 5.5x103 PFU. Spleens were harvested at day 7 for viral titration.
Using the Adobe Photoshop CS6 Rule Tool, a scale was calibrated using the
standard provided by the program, and an arbitrary unit (a.u.) of measurement was
constant throughout the scale. Spleen length according to this scale is written below
each organ. The majority of spleens harvested from GT KO mice exhibited
increased size relative to the spleen from an uninfected control. All spleens
harvested from WT B6 were comparable in size, or smaller, to spleens from the
uninfected mouse.

γMHV-68-infected GT-negative mice exhibited splenomegaly to a greater degree
than GT-positive mice. In order to quantify infection, real-time PCR analysis was
used to detect viral DNA present in infected GT-positive and GT-negative mice.
Mice aged 6-12 weeks were inoculated i.p. with γMHV-68 and spleens were
harvested at various days pi. As with in vitro experiments, absolute quantification
of viral copy number was not possible because no calibration standard was readily
available. Relative quantity of DNA was measured using an endogenous control;
for each experiment, the sample with the lowest quantity of viral DNA was used
as a standard to compare with the rest of the samples. The unit of measurement,
“fold change”, refers to a fold difference in quantity of DNA to the standard
sample. At 5 days pi, all GT-negative mice exhibited similar levels of viral DNA,



but a few GT-positive mice had 100’s to 1000’s-fold more DNA per gram in
splenic samples relative to the standard (Figure 23a). By day 7 pi, the majority of
mice from both groups expressed levels of viral DNA close to the standard.
At day 9 pi, the weight of individual spleens was also collected to see if size
correlated with the level of viral DNA expression. The average weight of a
healthy mouse spleen is between 80-140 mg. Gal-negative mice had spleen
weights ranging from 130-340 mg, while Gal-positive individuals had spleen
weights ranging from 90-140mg (Figure 23b). PCR results confirmed that the
larger spleens derived from Gal-negative mice. These spleens also contained
relatively higher amounts of viral DNA per gram compared to spleens from GTpositive mice. By day 11, both mouse types expressed relatively similar levels of
viral DNA (Figure 23c). Weights of spleens from GT-negative mice ranged from
120-270 mg and for GT-positive mice, 100-390 mg. Size of spleen again
correlates with the relative amount of viral DNA present in the organ. Data are
inconclusive for GT-dependent differential susceptibility to γMHV-68 infection.
At day 7 and 9 pi, GT-deficient mice have higher concentration of γMHV-68
virus in spleens, and greater splenomegaly, compared to GT-sufficient mice. But
this is likely not true at day 5 and day 11 pi. Working in relative quantities for
viral load makes it difficult to fully understand kinetics differences of γMHV-68
infections in the two mouse strains. More work with a calibration standard would
greatly elucidate the dynamics of viral infection between the two mouse types.





Figure 23: γMHV-68 infection on KO, WT and backcrossed mice. Mice aged
between 6-12 weeks were inoculated i.p. with 3.5x103 PFU (Day 5, 9 and 11 pi) or
5.5x103 PFU (Day 7). Spleen was harvested at various days pi for real-time PCR
analysis. (A) Spleens from 12-wk old mice harvested at day 5 pi, and spleens from 9
week old mice harvested at day 7 pi (B) Spleens from 11 week old mice were
harvested and weighed at day 9 pi (C) Spleens from 6 week old mice were harvested
and weighed at day 11 pi.



5.5 Adult WT and KO mice are equally permissive to SINV S.A.A.R86
infection
Findings from cell culture experiments indicated that SIN viruses preferentially
replicated in cells with an active GT gene, and it was important to confirm these
findings in an animal system. Most strains of SINV are avirulent in adult and
suckling mice. After approximately 2 weeks of age, mice can control infections
via an IFNα/β response, but for neonates that lack a functional IFN response (up
to 14 days of age), most SINV strains induce a severe, lethal viral encephalitis
(Reinarz et al., 1971; Ryman et al., 2000). Adult and suckling mice, however, are
susceptible to the neuroadapted S.A.A.R86 strain (Russell et al., 1989; Heise et
al., 2000; Ryman et al., 2000). To test for differences in susceptibility of KO and
WT mice to S.A.AR86, 8 to 9 week old male mice were inoculated i.p. with the
virus. From the i.p. route, the virus infects skin, muscle, and various visceral
organs and disseminates to the CNS via a viremia. Mice were sacrificed by
cervical dislocation, and blood, spleen, visceral fat pads or brain were harvested
from day 1 to 5 pi. Additionally, a group of mice was γ-irradiated to examine the
response of immunocompromised KO and WT mice to infection. Organs from
irradiated mice were harvested at day 6 pi and titrated for virus. At days 1 and 2
pi, mean viral titers from organ suspensions of blood, spleen and fat pad were
comparable between KO and WT mice (Figure 24a and 24b). At day 3, more
virus was found in the spleens of WT mice than KO mice, but the difference was
not statistically significant (Figure 24c). By day 5 pi, the virus was detected in
the brains of both KO and WT mice at comparable levels (Figure 24d). In





irradiated mice, at day 6 pi, no statistically significant difference in viral growth
in blood, spleen (Figure 24e), liver and fat pad (not shown) was observed between
GT-positive and GT-negative mice. These results indicate that adult WT and KO
mice are comparably susceptible to the virulent SINV S.A.AR86 strain.

Figure 24: S.A.A.R86 infections of WT and KO mice. Mice aged 8-9 weeks were
inoculated i.p. with 105 PFU in 200 μl. Blood, spleen, fat pads, or brain was
harvested at days 1, 2, 3 and 5. A second group of 8 week old mice was γ-irradiated
with 10Gy and inoculated with the same dose of virus. Blood, spleen, liver and fat
pad were harvested at day 6 pi. (A) Day 1 results are representative of pooled data
from two separate experiments performed under the same parameters (B) Day 2
results from blood, spleen and fat pad are also from pooled data from two separate
experiments (C) Only spleens were harvested for titration at day 3 pi (D) Only brain
was harvested at day 5 pi for titration (F) Titers from blood and spleen of γirradiated mice.



5.6 SINV infected WT suckling mice have accelerated symptom onset and
death compared to KO counterparts
In adult mice, no differences were observed in the response to SINV infection by
GT-sufficient or GT-deficient mice. However, very young mice are susceptible to
most SINV strains and could provide clues about host-specific differences in
response to infection. In order to determine this, GT KO and B6 mice aged 6 to
20 days were inoculated intracranially, because the virus is neurotropic, or
subcutaneously, to mimic the natural route of vector-borne infection. For these
experiments I used the less virulent AR339 strain and the more virulent S.A.AR86
strain. I tested a variety of ages for infection and found that mice infected at day
6 were not cared for by their mothers and that mice infected at day 20 were
resistant to the lethal effect of either strain. Infections of mice from 8 to14 days
of age resulted in 100% mortality, regardless of the presence or absence of αGT.
However, significant differences were observed in mean survival period prior to
death and onset of pathological symptoms. Intracranial infections of 8-day old
mice with the more virulent SINV S.A.AR86 resulted in a rapid onset of
spasmodic behavior and lethargy. All WT mice died by day 3 and a few KO mice
survived until day 4, but this difference was not statistically significantly. Figure
26 shows an experiment where 8-day old WT mice infected i.c. with SINV
AR339 had a shorter mean survival time than KO mice (3.0 vs. 4.0 days). WT
mice exhibited spasms and trembling, unsteady locomotion as early as 24 h after
inoculation and succumbed to infection beginning at 2 days post infection (Figure
25). In contrast, KO mice experienced morbidity around day 2 and 3 and began





dying at day 4. Thirteen day-old KO mice inoculated subcutaneously with
S.A.AR86 had a longer mean survival time compared to WT mice (5.0 vs. 4.0
days) and experienced weight loss later than WT mice (day 3 vs. day 2). Shaking
and hind limb paralysis were observed by day 2 in WT mice and on day 4 in GT
KOs. At fourteen days of age, both KO and WT mice began dying on day 4 pi
and survived until day 6 pi, and showed no significant differences in survival
times and symptomology. These data reflect the same pattern of susceptibility to
SINV seen with cultured cells. Altogether, these data show that GT-sufficient
suckling mice have increased sensitivity to the lethal effects of SINV compared to
GT KO counterparts. GT KO mice eventually succumb to infection, but the onset
of pathological symptoms and death are significantly delayed.





Figure 25: SINV infections of KO and WT weanling mice. A) Eight-day old mice
were inoculated intra-cranially with approximately 200 pfu SINV HR strain in 10 μl
of media (2 litters KO n=15, 2 litters WT n=13) or (B) 13-day old mice were
inoculated subcutaneously with approximately 1.68x103 PFU of SINV S.A.AR86 in
30μl (3 litters KO n=17, 2 litters WT n=10).

To determine if differences in survival time and disease progression in GTsufficient and GT-deficient suckling mice correlate with differences in viral
replication in the brain, eight-day old mice were infected i.c. with either a high



dose (1.16x106) or low dose (200 PFU) of SINV AR339. With a high dose of
virus, the effects of an abundant infection can be observed, as a high number of
cells should be infected. With a low dose, the ability of a virus to replicate within
the host can be observed, as few cells should be initially infected. The F1xB6
generation of mice was used in lieu of WT to represent a GT-sufficient host
because these mice were readily available and age matched to the KOs. This
group was given the high dose. For the low dose experiment, age-matched GTsufficient and GT-deficient counterparts were not available, but a litter of F1xKO
mice was. Each mouse had a 50% chance of either expressing or not expressing
the GT gene; a mix of GT-expressing and GT non-expressing individuals in the
group was likely. These mice were used to compare viral replication in the brain
from a lower dose of virus. For high-dose and low-dose experiments, brains from
KO and WT mice were harvested at 24 h pi and titrated for virus. At 24 h pi,
titers from brain suspensions of all three types of mice reached levels of up to
6x108 PFU/mL, regardless of the initial inoculum, or possible genotype of the
mouse (Figure 26). These data suggest that viral replication is not curtailed in
GT-deficient mice relative to GT-sufficient mice. Delayed onset of disease and
death in GT KO mice does not appear to be correlated with inhibition of viral
replication in the brains of these mice.





Figure 26: SINV AR339 infections of KO and backcrossed mice. Eight-day old GT
KO and genetically crossed (F1xB6) mice were give a high dose of virus, 1.1x106
PFU. F1xKO were inoculated with a lower dose of 200 PFU. Brains were harvested
24 h pi.

In vivo experiments have demonstrated that KO mice for the GT gene are more
susceptible to HSV-2 infection compared to GT-sufficient mice. This parallels
the results from in vitro studies, which show that GT expression in a host cell
decreases susceptibility to herpes virus infection. Results from experiments using
genetically crossed mice to verify the greater susceptibility of αGal-negative mice
to HSV 1 and 2 were not as conclusive, and it is possible that a biological factor
in the KO mice affects their response to infection, prior to being crossed with WT
B6 mice. However, results from these experiments are difficult to interpret
because the true level αGal expression in individual mice was difficult to assess.
Results from experiments with γMHV-68 to verify greater susceptibility in KO
mice to other herpes viruses were also not consistent with in vitro findings. More
work with this virus is necesseary to verify results. For Sindbis virus infections,



suckling mice that express the GGTA1 gene experience faster onset of
pathological symptoms and death compared to GT-deficient mice. This also
parallels in vitro data where SINV shows greater infectivity in GT-positive hosts.
Overall, in vivo data support my hypothesis that host susceptibility to different
viral infections is dependent on the expression or non-expression of GGTA1 in the
host.





CHAPTER 6
DISCUSSION AND CONCLUSIONS

The present study provides the first investigation on the infection dynamics of
viruses in the presence and absence of the α1,3-galactosyltransferase (GGTA1)
gene. I have shown that the loss of GT expression rendered cells more resistant to
several viruses belonging to the Sindbis group but more sensitive to various
herpes viruses, regardless of αGal expression or non-expression on the infecting
viruses. Additionally, differences in efficiency of infection were seen with SINV
and herpes viruses, but once productively infected, host cells generally expressed
similar amounts of viral protein as indicated by GFP expression. This points to a
role for GT activity or a GT product early during the course of an infection. At
the organismic level, I have shown that SINV strains are more virulent to GTexpressing young mice compared to GT-deficient suckling mice. In contrast,
adult WT mice infected with HSV-2 exhibited less pathology and lower viral
replication compared to KO mice. These findings demonstrate that the presence
of the GT enzyme in a host can alter their susceptibility to viral infection. This
study also provides insight on the evolution of disease resistance in catarrhine
primates. The significance of a mutation that occurred approximately 28 Ma, that
inactivated GGTA1, and modified the carbohydrate repertoire of the ancestors of
catarrhine primates, is not fully understood. Here, I provided evidence that this
mutation had the capacity to significantly alter host resistance to viral infections,
and I speculate that this change in resistance to infections may have provided a





selective advantage to individuals harboring the mutation. In this study, SINV
grew to 10-20 fold higher in GT-positive cells and caused more rapid death in
GT-positive suckling mice. Selection may have acted on the GT locus, directly
altering host cell susceptibility to virulent infection. However, the mechanism by
which GT-dependent differential susceptibility to viruses operates still remains to
be deciphered. It is important to once again note that the viruses examined in this
study would not have been the putative selection agents of 28 million years ago.
While it may not be possible to identify the pathogenic agent that exerted
selective pressure on the GT locus, it is possible to conjecture that loss of GT
expression rendered ancestral catarrhines more resistant to a virus or other
pathogens with the ability of modern day SINV strains to favorably replicate in
GT-positive hosts.

It is more difficult to explain how a mutation that enhanced susceptibility to some
viruses, as was observed with contemporary strains of HSV, could also be
advantageous to the host. It is very possible that HSV evolved specificity for
cells that did not express surface αGal after the mutation became fixed in the
population. For instance, selective pressure from Plasmodium reichenowi (Martin
et al., 2005) likely led to loss of expression of the terminal sialic acid, Neu5Ac, a
product of the CMAH gene, in the ancestral hominin lineage around 3 Ma
(Orlandi et al., 1992; Chou et al., 1998; Hayakawa et al., 2001: Hayakawa et al.,
2006). The inactivation of the CMAH gene presumably rendered humans less
susceptible to malarial infections for some time until the Plasmodium parasite





evolved the ability to exploit the mutated site once again (Hayakawa et al., 2001;
Rich et al., 2009). Today, that domain is still under strong selective pressure from
Plasmodium and other pathogens (Martin et al., 2005), clearly indicating that
host-pathogen relationships are not static. In a similar manner, inactivation of
GGTA1 may have provided ancestors of catarrhines with temporary relief from a
virulent pathogen that exerted pressure on that locus, but this would not have
eliminated the ability of other (even related) pathogens to exploit hosts expressing
ΔGGTA1. It is also of interest that herpes virus infections can sometimes benefit
the chronically infected host. Recent work with mice has shown that herpes virus
latency can induce a state of heightened NK cell activity that results in swifter
action against new infections, and certain human herpesvirus infections may have
similar properties (White et al., 2012). Furthermore, the periodic activation of
latent or persistent viruses can induce chronic IFN-γ secretion and macrophage
activation that can provide cross protection against acute bacterial infections
(Barton et al., 2007).

The greater susceptibility of GT KO mice to HSV-2 compared to WT B6 mice
was evident, but the greater susceptibility of crossed mice that expressed low
levels of αGal compared to mice that expressed high levels of αGal, was much
less clear. Overall, GT-negative mice presented slightly higher viral titers and
greater pathology than GT-positive mice, but the data were not as definitive as
that obtained from infections with the parental strains of mice. Additionally,
infections of crossed mice with HSV-1 did not show differences in response to





virus between αGal expressors and non- or low expressors. This could indicate
that the susceptibility of GT KO mice may be due to a factor that is present in the
mice prior to crossing with the WT, or alternately, increased resistance of crossed
mice may be due to a factor that is present in the WT mice they are crossed with.
In either scenario, the response would be independent of the GGTA1 gene or
αGal. It is important to note however, that interpreting results of experiments
using the genetically crossed mice was made difficult because assessing the level
of αGal expression in individual mice was problematic. The expression of αGal
was measured by BSl binding to Thy 1.2 cells derived from blood of gammairradiated mice, but the small fraction of remaning Thy 1.2 cells post-irradiation
may not be an accurate representation of αGal expression in the individual mice.
More precise tests to assess genotype-phenotype associations, such as genetic
tests, in addition to antibody binding tests of blood lymphocytes, would be highly
useful in these experiments. In this way, a better understanding of the correlation
between homozygotes to an HSV response could be measured, in conjunction
with a response to virus by heterozygotes that express varying levels of αGal on
their cell surfaces.

In cell culture, HSV-1 preferentially grew in cells that were GT-negative and this
was not corroborated in vivo. Wild type and KO mice showed no significant
differences in HSV-1 titers from lung suspensions at various days post infection.
αGal sites are found on all tissues (except sperm cells) of the body in GTsufficient species (Thall et al., 1995), but the level of expression on different





tissues can vary, as can the level of expression by individual. Thus, the level of
expression on the specific cell the virus infects may determine susceptibility of
the entire host. HSV-1 infections were performed intranasally, and αGal
expression is abundant in the vomeronasal organ (Koike et al., 2007). Variable
expression of αGal at the site of inoculation may not explain the comparable
levels of HSV-1 viral replication between WT and KO mice as measured from
lung suspensions. However, it is possible that route of infection and organs
accessible for viral dissemination may influence the outcome of infection. For
example, i.p. inoculation of HSV-1 often results in subclinical infections barely
detectable in visceral organs (Renis et al., 1976), but i.n. inoculation causes
obvious disease in the lung. It is possible that GT expression plays no role in
HSV-1 infections in vivo, but it is important that other routes of infection (e.g.,
intracranial, corneal) that result in measurable infection, and the level of αGal
expression in infected tissues, be tested in order to verify this possibility.

Results from in vivo infections with γMHV-68 are not easy to interpret because of
repeatability issues with these assays. Titers derived from mice of the same
genotype were highly variable, whereby some animals had quantities of virus
many-fold higher than their littermates, and littermates would be expected to react
similarly to infection. A possibility is that the immune system interacts with the
virus and influences the outcome of γMHV-68 infection in individual mice. In
addition, each experiment was completed once and therefore must be repeated
with the same parameters to verify results. Precise quantification of viral DNA





would also benefit these experiments. Relative quantification of viral DNA was
informative about differences in infection levels between individuals, but it was
difficult to assess whether a relatively low amount of viral DNA indicated viral
clearance or was simply the lowest measured quantity of very high levels of
replication. Two experiments did show that the majority of KO mice exhibited
splenomegaly while WT mice presented spleens that were comparable in size to
that of uninfected control mice. This could indicate that more B cells are infected
and accumulated in the spleens of KO mice compared to the WT, but additional
experiments are necessary to clarify whether this observed difference is real.
Fatality in suckling mice is associated with neuronal damage (Johnson, 1965;
Tucker et al., 1993). Interestingly, WT suckling mice succumbed to SINV
infection and experienced disease significantly earlier than their KO counterparts,
despite having similar viral titers in brain tissue. One explanation for this is that
viral replication within cells of both mouse types is comparable, but dissemination
of the virus—and thus amount of tissue damage—is restricted. Infections in cell
culture showed that the susceptible GT-negative population was limited to a small
subpopulation, and if this phenomenon translates in vivo, viral spread in brain
tissue of KO mice may be slowed by the absence of GT expression. As in cell
culture, viral replication is not impeded in the mouse brains, but the extent of
neuron involvement may be sufficiently limited to delay onset of disease
symptoms and death. Histology work of SIN GFP infected suckling mouse brains





would elucidate this point. Additionally, titration of other tissues from these mice
would be informative regarding dissemination of the virus, and how extra-neural
tissue involvement affects virulence.

The possible mechanism by which expression of the GT gene alters the course of
viral infections is by inhibiting the ability of a virus to initiate infection. I
hypothesized that αGal is involved in viral-host interactions during entry because
αGal is a known active binding receptor to other pathogens, such as Clostridium
difficile. However, results from experiments to support my hypothesis have not
been conclusive. Fluorescence focus assays showed that GT-negative cells
appeared to resist infection by SINV viruses, and even after long periods of
incubation with virus and after several rounds of viral replication, a large fraction
of cells remained uninfected. The BL6 cell population likely represents a
heterogeneous group in terms of their permissiveness to SINV infection that
includes high- and low-permissive clones. Previous work (Kim et al., 1993) with
the MA-104 cell line, derived from monkey kidney cells, showed that upon
infection with porcine reproductive and respiratory syndrome (PRRS) virus, cells
produced low viral titers and monolayers showed focal cytopathic effects. The
parental MA-104 cell line yielded two subpopulations with different
susceptibilities to PRRS infection, high- and low-permissive cell clones (Kim et
al., 1993). Infections on a different cell line, the PK15 porcine cell line, with the
porcine circovirus type 2 (PCV2), demonstrated that only about 20% of the
population was susceptible to infection (Zhu et al., 2007). High- and low-





permissive clones were also demonstrated in the porcine cell lines. In SINV
infection assays, BL6 cells showed similar characteristics to the parental MA-104
and PK15 cell lines. SINV-infected BL6 cells produced relatively low titers that
appeared to derive from a fraction of the cell population, and monolayers
exhibited focal cytopathic effects. In contrast, SINV-infected BL6αGal cells
yielded relatively high titers and monolayers were uniformly infected and lysed
by virus infection. If BL6 cells produce clones with differences in their
susceptibility to SINV, it is important to identify the factor that permits
propagation in permissive cells. Perhaps results from experiments with αgalactosidase can provide an explanation. It can be argued that herpes virus
infections on the BL6αGal cells may also exhibit a similar phenomenon as
described above. However, assays with HSV-1 GFP showed that infection on
BL6αGal cells was almost negligible, indicating that, at least with HSV-1 GFP,
the cells in the population were comparably non-permissive to infection.

Enzymatic treatment of BL6 cells reduced infectivity of αGal-positive cells,
possibly due to the loss of surface αGal. However, this enzyme also further
reduced the low level infectivity in αGal-negative cells that do not have a
functional GT gene. BL6 cells may still express low levels of terminal
Galα1,3Gal residues via an additional glycosyltransferase, the iGb3S enzyme
(Taylor et al., 2003; Milland et al., 2006). iGb3S enzyme activity has been
observed in rats (Taylor et al., 2003) and in GT KO mice and pigs (Milland et al.,
2006). Our cell lines were consistently monitored for expression of αGal using





anti-Gal and BSl, but αGal was not detected in BL6 cells. This may be because as
shown in KO mice, detection by BS lectin or anti-Gal is poor as the αGal
disaccharide expressed via iGb3S synthesis is restricted to glycolipids. The sites
in KO mice are recognized by monoclonal antibodies produced from GGTA-/mouse splenocytes fused to NS-1 hybridoma cells (Milland et al., 2006). BL6
cells could potentially express barely detectable levels of iGb3S derived αGal
residues, the presence (and removal) of which may have some effect on infection
in these cells. Alternatively, BL6 cells may express terminal galactose
monosaccharides in variable amounts that may not be detectable by anti-Gal or
BSl binding but are removed by enzymatic treatment. The α-galactosidase
enzyme has high specificity for terminal galactose substrates, which means the
enzyme removes the terminal galactose from proteins that express the Galα1,3Gal
structure, but it will also remove αGal residues from the surface of human red
blood cells with the group B structure, Galα1,3Fuc (Zhu et al., 1996). It is
possible that while SINV may have greater affinity with the Gal-Gal linkage,
resulting in a more productive infection of BL6αGal cells, the virus may also have
some affinity for αGal monosaccharides. SINV may infect BL6 cells that express
certain levels of terminal galactose residues, the removal of which affects
infectivity. These observations should be further investigated.

The involvement of αGal in the course of viral infections is thus an avenue that
warrants further investigation. Cellular glycans and host glycosylation pathways
play an important role in viral infections (Reitter and Desrosiers, 1998; Varki and





Varki, 2007; Vigerust and Sheperd, 2007), and in this way the distribution of
host-cell carbohydrates may even determine host range and tissue tropism
(Schenider-Schaulies, 2000; Suzuki et al., 2000). SIN viruses have widespread
host repertoires and utilize the ubiquitously expressed protein NRAMP2 for
binding and entry into host cells (Rose et al., 2011; Stiles et al., 2011). It is
unlikely that αGal would be a required receptor utilized in entry for SINV strains
because loss of αGT expression limits, but does not completely inhibit viral
infection. Further, insect cells such as those of Aedes mosquitos, which SINV
infects, lack terminal glycosylation from galactosyltransferases and
sialyltransferases (Butters et al., 1981). The most common terminal glycan
expressed on SINV virions propagated in Aedes-derived cells is mannose (Hsieh
et al., 1984). On mammalian cells, αGal may instead participate in attachment or
binding of SINV in a process analogous to how the virus may utilize heparan
sulfate (Byrnes and Griffin, 1998); these receptors may promote initial adherence
to host cells until higher affinity receptors are engaged (Schneider-Schaulies,
2000). Loss of heparan sulfate on host cells reduces SINV infection, but does not
abrogate it. HSV-1 and 2 entry into cells is a multi-step process initiated by viral
glycoproteins binding to cellular heparan sulfate proteoglycans (WuDunn and
Spear, 1989; Shieh et al., 1992; Shukla et al., 1999; Spear and Longnecker, 2003)
followed by binding to entry receptors such as the herpesvirus entry mediator
(HVEM) protein or nectin-1 and nectin-2 and includes other virion-cellular
protein interactions (Whitbeck et al., 1997; Shukla et al., 1999; Spear and
Longnecker, 2003). Active expression of the αGT gene highly impairs infection





of both herpes virus strains. Experimental blocking of viral glycoprotein
interactions with cognate cellular proteins disrupted the entry processes and
inhibited infection of HSV-1 (Whitbeck et al., 1997; Gianni et al., 2010). It is
conceivable that the presence of αGal on the cellular surface could somehow alter
the interactions of binding or entry receptors and result in reduced infection
efficiency for these herpesviruses.

Pathogens are major drivers of evolution, but conservation work has shown it is
often the case that synergistic causes are responsible for reducing the number of
individuals in populations to the brink of extinction (Brook et al., 2008). As such,
climate change can influence ecosystems and animal biodiversity via altering
pathogen or host biological processes (Harvell et al., 2002). Recent studies on
global climate change and infectious disease (Reiter, 2001; Harvell et al., 2002;
Lafferty, 2009; Mills et al., 2010) have focused on the effects of warming
climates on disease, likely due to the present-day warming phase, but it is
conceivable that measurable climate change of any sort could affect the disease
ecology of populations experiencing these changes. The Oligocene was a period
of vast climatic and geological change that also coincides with a great
chronological gap in the primate paleontological record (Seiffert, 2007). While
the particular ecological conditions that basal catarrhines experienced in the
Oligocene are not known, the world underwent climatic changes that affected
animal habitats and the distribution of life on the planet. In general, the fossil
record shows a vast turnover of faunal species found at the Eocene-Oligocene





boundary and those present at the Oligocene-Miocene boundary (Seiffert, 2007;
Kappelman et al., 2003). For catarrhines, the scarcity of fossils that derive from
the Oligocene makes it difficult to discern phylogenetic relationships between
ancestral and descendant taxa, and to even estimate conclusive divergence dates
for OWM and apes (Raaum et al., 2005; Steiper and Young, 2008; Perelman et
al., 2011). Numerous factors may have affected Oligocene primate evolution and
lineage divergence. GGTA1 inactivation around 28 Ma can inform us on timing
of phylogenetic divergences; the work presented in this dissertation can inform us
on one possible catalyst for lineage divergence in ancestral catarrhines.
Pathogens with wide host-specificity can cause declines across sympatric
populations and lineage divergence can result when less resistant populations
within a species are culled (Van Blerkom, 2003). In cases where genetic diversity
is useful, polymorphism may be selected for in the population, such as with the
major histocompatibility group of genes; however, specific alleles are favored
when selection is directional (Van Blerkom, 2003). In the case of the GGTA1
gene, the mutated gene (ΔGGTA1) may have been favored if GGTA1 or its gene
product could be exploited by a virulent pathogen. Any factor that increases
resistance to a pathogen or decreases infectivity of that pathogen is enough to
increase fitness for an individual (Antonovics et al., 2013). If the hypotheses
tested during this research are correct, the loss of α1,3GT expression may have
given αGal-negative catarrhines an advantage over αGal-positive catarrhines in
controlling pathogens that could exploit the α1,3GT pathway without also
stimulating an autoimmune response. Additionally, the production of anti-Gal





antibodies would have further protected GT-negative species from zoonotic
transmission. Viruses can shape the evolutionary trajectory of the organisms they
infect, as well those that the infected organisms are in contact with. Experimental
evidence on the significance of α1,3GT activity and αGal expression in viral
disease such as that presented here may shed light on the processes that helped
shape catarrhine evolution during the Oligocene epoch.





APPENDIX
LIST OF ABBREVIATIONS
αGal
α1,3GT or GT
ΔGGTA1
γMHV-68
ab
ANOVA
APC
BSl-B4 or BSl
CCR5
cDNA
CHIK
CMAH
CMP
 
! 
 !"$
  
 
FACS
FBS
FCS
FITC
FSL
GFP

  " 
Gy
GYPA
! 
 
HIV 
+, 
+- 
**

**

*!*

 
 


  
























α1,3galactosyl
α1,3galactosyltransferase
mutated ( !" $)( #($"#"#,
murine gammaherpes virus 68
antibody
analysis of variance
allophycocyanin
lectin from Bandeiraea simplicifolia
leukocyte chemokine (C-C motif) receptor 5
complementary DNA
Chikungunya virus
cytidine monophosphate-N-acetylneuraminic acid
hydroxylase
cytidine monophosphate
$""& %##(#$
(#! #$$ 
$&$""!"$
$(#% '
!#$+""&"%#
fluorescence-activated cell sorting
fetal bovine serum
fetal calf serum
fluorescein isothiocyanate
functional spacer lipid construct
green fluorescent protein
( !" $)( #($"#"#,
GGTA1  %$
gray unit
glycoprotein A
 %"#! #$$ 
haemagglutin
human immunodeficiency virus
"!##!'&"%#$(!,
"!##!'&"%#$(!-
$""
$"#
$"!"$ 
$ %#$"##(
$"" 
%  %
(! ($ " $#&"%#

,,.

 
 
  
 
 
  
 
 
 
 
PBS
PCR
PFU
pi
PPG
PV
R-PE
 
  
#)) 
  
 
ST6GAL1
UMMS
UPG
VSV
VZV
WEE
WNV 
 
+
























%"($  &"%#
 %#"( " #$
##$%
% "#$#$(
 %#!$$#&"%#
$"
%$!$( $ 
' " (
$%""
 " (

phosphate buffered saline
polymerase chain reaction
plaque forming units
post infection
processed pseudogene
Pichinde virus
R-phycoerythrin
" 
$"" 
#%%$ %#
#&"%#
 "#$&"%#
ST6 beta-galactosamide alpha 2,6-sialiyltranferase 1
University of Massachusetts Medical School
unprocessed pseudogene
vesicular stomatitis virus
varicella-zoster virus
Western equine encephalitis virus
#$ &"%#
'$(!
'$(!C57BL/6J

**,

BIBLIOGRAPHY
Adler, H., Beland, J.L., Del-Pan, N.C., Kobzik, L., Brewer, J.P., Martin, T.R.
and I.J. Rimm. 1997. Suppression of herpes simplex virus type 1 (HSV-1)induced pneumonia in mice by inhibition of inducible nitric oxide synthase
(iNOS, NOS2). Journal of Experimental Medicine 9:1533-1540.
Agrawal, P. and R. Garg. 2012. Fulminant leukemoid reaction due to
postpartum Clostridium sordellii infection. Journal of Global Infectious Disease
4:209-211.
Almeida, I.C., Milani, S.R., Gorin, P.A. and L.R. Travassos. 1991.
Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human
anti-alpha-galactosyl antibodies. The Journal of Immunology 146:2394-2400.
Angata, T. and A. Varki. 2002. Chemical diversity in the sialic acids and related
α-Keto acids: an evolutionary perspective. Chemical Reviews 102:439-469.
Antonovics, J., Boots, M., Ebert, D., Koskella, B., Poss, M. and B.M. Sadd.
2012. The origin of specificity by means of natural selection: evolved and nonhost
resistance in host-pathogen interactions. Evolution 67:1-9.
Availa, J.L., Rojas, M. and U. Galili. 1989. Immunogenic Gal alpha1,3Gal
carbohydrate epitopes are present on pathogenic American Trypanosoma and
Leishmania. The Journal of Immunology 142:2828-2834.
Babu, J.S., Thomas, J., Kanangat, S., Morrison, L.A., Knipe, D.M. and B.T.
Rouse. 1996. Viral replication is required for induction of ocular
immunopathology by herpes simplex virus. Journal of Virology 70:101-107.
Bähr, A. and E. Wolf. 2012. Domestic animal models for biomedical research.
47(s):59-71.
Baker, D.A. and S.A. Plotkin. 1978. Enhancement of vaginal infection in mice
by herpes simplex virus type II with progesterone. Experimental Biology and
Medicine 158:131-134.
Barton, E.S., White, D.W., Cathelyn, J.S., Brett-McClellan, K.A., Engle, M.,
Diamond, M.S., Miller, V.L. and H.W. Virgin. 2007. Herpesvirus latency
confers symbiotic protection from bacterial infection. Nature 447:326-330.
Bedell, M.A., Jenkins, N.A. and N.G. Copeland. 1997. Mouse models of human
disease. Part 1: Techniques and resources for genetic analysis in mice. Genes &
Development 11:1-10.





Bermejo, M., Rodriguez-Teijeiro, J.D., Illera, G., Barroso, A., Vila, C. and
P.D. Walsh. 2006. Ebola outbreak killed 5000 gorillas. Science 314:1564.
Biedler, J.L., Helson, L. and B.A. Spengler. 1973. Morphology and growth,
tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous
culture. Cancer Research 33:2643-2652.
Bishop, J.R. and P. Gagneux. 2007. Evolution of carbohydrate antigens—
microbial forces shaping host glycomes? Glycobiology 17:23R-34R.
Brabec, R.K., Peters, B.P., Bernstein, I.A., Gray, R.H. and I.J. Goldstein.
1979. Differential lectin binding to cellular membranes in the epidermis of the
newborn rat. Proceedings of the National Acadamy of Sciences of the United
States of America 77:477-479.
Bradfute, S.B., Warfield, K.L., and M. Bray. 2012. Mouse models for filovirus
infections. Viruses 4:1477-1508. [doi:10.3390/v4091477].
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. and J. Huggins. 1998. A
mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic
fever. Journal of Infectious Diseases 178:651-661.
Brinkman-Van der Linden, E.C.M., Sjoberg, E.R., Juneja, L.R., Crocker,
P.R., Varki, N. and A. Varki. 2000. Loss of N-glycolylneuraminic acid in
human evolution: Implications for sialic acid recognition by siglecs. The Journal
of Biological Chemistry 275:8633-8640.
Brook, B.W., Sodhi, N.S. and J.A. Bradshaw. 2008. Synergies among
extinction drivers under global change. Trends in Ecology and Evolution 23:453460.
Burge, B.W. and E.R. Pfefferkorn. 1966. Isolation and characterization of
conditional-lethal mutants of Sindbis virus. Virology 30:204-213.
Byrnes, A.P and D.E. Griffin. 1998. Binding of Sindbis virus to cell surface
heparan sulfate. Journal of Virology. 72:7349-7356.
Castronovo, V., Colin, C., Parent, B., Foidart, J-M., Lambotte, R. and P.
Mahieu. 1989. Possible role of human natural anti-gal antibodies in the natural
antitumor defense system. Journal of the National Cancer Institute 81:212-216.
Chatterjee, H.J., Ho, S.Y.W., Barnes, I. and C. Groves. 2009. Estimating the
phylogeny and divergence times of primates using a supermatrix approach. BMC
Evolutionary Biology 9:259. [Open Access doi:10.1186/l471-2148-9-259].





Chou, H-H., Takematsu, H., Diaz, S., Iber, J., Nickerson, E., Wright, K.L.,
Muchmore, E.A., Nelson, D.L., Warren, S.T. and A. Varki. 1998. A mutation
in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence.
Proceedings of the National Academy of Sciences of the United States of America
95:11751-11756.
Clark, G.F., Krivan, H.C., Wilkins, T.D. and D.F. Smith. 1987. Toxin A from
Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal
Galα1,3Galβ1,4GlcNAc sequences. Archives of Biochemistry and Biophysics.
257:217-229.
Crawley, J.N. 1999. Behavioral phenotyping of transgenic and knockout mice:
experimental design and evaluation of general health, sensory functions, motor
abilities, and specific behavioral tests. Brain Research 835:18-26.
Ducrocq, S., Manthi, F.K. and F. Lihoreau. 2011. First record of a parapithecid
primate from Oligocene of Kenya. Journal of Human Evolution 61:327-331.
Figueirido, B., Janis, C.M., Pérez-Claros, J.A., De Renzi, M.D. and P.
Palmqvist. 2012. Cenozoic climate change influences mammalian evolutionary
dynamics. Proceedings of the National Acadamy of Sciences 109:722-727.
Gagneux, P., Cheriyan, M., Hurtado-Ziola, N., Brinkman van der Linden,
E.C.M., Anderson, D., McClure, H., Varki, A. and N.M. Varki. 2003. Humanspecific regulation of α2-6-linked sialic acids. The Journal of Biological
Chemistry 278:48245-48250.
Galili, U., Rachmilewitz, E.A., Peleg, A. and I. Flechner. 1984. A unique
natural human IgG antibody with anti-α-galactosyl specificity. Journal of
Experimental Medicine 160:1519-1531.
Galili, U., Macher, B.A., Buehler, J. and S.B. Shohet. 1985. Human natural
anti-α-galactosyl IgG: The specific recognition of α(1-3)-linked galactose
residues. Journal of Experimental Medicine 162:573-582.
Galili, U., Clark, M.R., Shohet, S.B., Buehler, J. and B.A. Macher. 1987.
Evolutionary relationship between the natural anti-Gal antibody and the
Galα1,3Gal epitopes in primates. Proceedings of the National Academy of
Sciences of the United States of America 84:1369-1373.
Galili, U., Mandrell, R.E., Hamadeh, R.M., Shohet, S.B. and J.M. Griffiss.
1988. Interaction between human nautral anti-α-galactosyl immunoglobulin G and
bacteria of the human flora. Infection and Immunity 56:1730-1737.





Galili, U. and K. Swanson. 1991. Gene sequences suggest inactivation of α-1,3galactosyltransferase in catarrhines after the divergence of apes from monkeys.
Proceedings of the National Academy of Sciences 88:7401-7404.
Galili, U. 1993. Interactions of the natural anti-Gal antibody with the α-galactosyl
epitopes: a major obstacle for xenotransplantation in humans. Immunology Today
14:480-82.
Gao, M. and D.M. Knipe. 1991. Potential role for herpes simplex virus ICP8
DNA replication protein in stimulation of late gene expression. Journal of
Virology 65:2666-2675.
Gastinel, L.N., Bignon, C., Misra, A.K., Hindsgaul, O., Shaper, J.H. and D.H.
Joziasse. 2001. Bovine α1,3-galactosyltransferase catalytic domain structure and
its relationship with ABO histo-blood group and glycosphingolipid
glycosyltransferases. The EMBO Journal 20:638-649.
Germi, R., Crance, J-M., Garin, D., Guiment, J., Lortat-Jacob, H., Ruigrok,
R.W.H., Zarski, J-P. and E. Drouet. 2002. Heparan sulfate-mediated binding of
infectious Dengue virus type 2 and Yellow fever virus. Virology 292:162-168.
Gianni, T., Cerretani, A., DuBois, R., Salvioli, S., Blystone, S.S., Rey, F. and
G. Campadelli-Fiume. 2010. Herpes simplex virus glycoproteins H/L bind to
cells independently of αVβ3 integrin and inhibit virus entry, and their constitutive
expression restricts infection. Journal of Virology 84:4013-4025.
Gorelik, E., Duty, L., Anaraki, F. and U. Galili. 1995. Alterations of cell
surface carbohydrates and inhibition of metastatic properties of murine
melanomas by α1,3 galatosyltransferase gene transfection. Cancer Research
55:4168-4173.
Gresikova, M., Sekeyova, M., Tempera, G., Guglielmino, S., and A. Castro.
1978. Identification of a Sindbis virus strain isolated from Hyaloma marginatum
ticks in Sicily. Acta Virologica 22:231-232.
Hamadeh, R.M., Jarvis, G.A., Galili, U., Mandrell, R.E., Zhou, P. and J.M.
Griffiss. 1992. Human natural anti-Gal IgG regulates alternative complement
pathway activation on bacterial surfaces. The Journal of Clinical Investigation,
Inc. 89:1223-1235.
Hamadeh, R.M., Jarvis, G.A., Zhou, P., Cotleur, A.C. and J.M. Griffiss.
1996. Bacterial enzymes can add galactose α1,3 to human erythrocytes and create
a senescence-associated epitope. Infection and Immunity 64:528-534.
Hart, I. 1979. The selection and characterization of an invasive variant of the B16
melanoma. American Journal of Pathology 97:587-600.





Harvell, C.D., Mitchell, C.E., Ward, J.R., Altizer, S., Dobson, A.P., Ostfeld,
R.S. and M.D. Samuel. 2002. Climate warming and disease risks for terrestrial
and marine biota. Science 296:2158-2162.
Hayakawa, T., Satta, Y., Gagneux, P., Varki, A. and N. Takahata. 2001. Alumediated inactivation of the human CMP-N-acetylneuraminic acid hydroxylase
gene. Proceedings of the National Acadamy of Sciences 98:11399-11404.
Hayakawa, T., Aki, I., Varki, A., Satta, Y. and N. Takahata. 2006. Fixation of
the human-specific CMP-N-acetylneuraminic acid hydroxylase pseudogene and
implications of haplotype diversity for human evolution. Genetics 172:1139-1146.
Hedlund, M., Tangvoranuntakul, P., Takematsu, H., Long, J.M., Housley,
G.D., Kozutsumi, Y., Suzuki, A., Wynshaw-Boris, A., Ryan, A.F., Gallo, R.L.,
Varki, N. and A. Varki. 2007. N-Glycolylneuraminic acid deficiency in mice:
implications for human biology and evolution. Molecular and Cellular Biology
27:4340-4346.
Heise, M.T., Simpson, D.A. and R.E. Johnston. 2000. A single amino acid
change in nsP1 attenuates neurovirulence of the Sindbis-group alphavirus
S.A.A.R86. Journal of Virology 74:4207-4213.
Hsieh, P. and P.W. Robbins. 1984. Regulation of Asparagine-linked
oligosaccharide processing: Oligosaccharide processing in Aedes albopictus
mosquito cells. The Journal of Biological Chemistry 259:2375-2382.
Hütter, G. and S. Ganepola. 2011. The CCR5-delta32 polymorphism as a model
to study host adaptation against infectious diseases and to develop new treatment
strategies. Experimental Biology and Medicine 236:938-943.
Jackson, T. Ellard, F.M., Ghazaleh, R.A., Brookes, S.M., Blakemore, W.E.,
Corteyn, A.H., Stuart, D.I., Newman, J.W. and A.M. King. 1996. Efficient
infection of cells in culture by type O foot-and-mouth disease virus requires
binding to cell surface heparan sulfate. Journal of Virology 70:5282-5287.
Johnson, R.T. 1965. Virus invasion of the central nervous system, a study of
Sindbis virus infection in the mouse using fluorescent antibody. The American
Journal of Pathology 46:929-943.
Joziasse, D.H., Shaper, J.H., Jabs, E.W. and N.L. Shaper. 1991.
Characterization of an α1,3-galactosyltransferase homologue on human
chromosome 12 that is organized as a processed pseudogene. The Journal of
Biological Chemistry 15:6991-6998.





Kagawa, Y., Takasaki, S., Utsumi, J., Hosoi, K., Shimizu, H., Kochibe, N. and
A. Kobata. 1988. Comparative study of the asparagine-linked sugar chains of
natural human inferferon-β1 and recombinant human interferon-β-1produced by
three different mammalian cells. The Journal of Biological Chemistry 33:1750817515.
Kappelman, J., Rasmussen, D.T., Sanders, W.J., Feseha, M., Brown, T.,
Copeland, P., Crabaugh, J., Fleagle, J., Glantz, M., Gordon, A., Jacobs, B.,
Maga, M., Muldoon, K., Pan, A., Pyne, L., Richmond, B., Ryan, T., Seiffert,
E.R., Sen, S., Todd, L., Wiemann, M.C. and A. Winkler. 2003. Oligocene
mammals from Ethiopia and faunal exchange between Afro-Arabia and Eurasia.
Nature 426:549-552.
Kastrukoff, L.F., Lau, A.S. and M.L. Puterman. 1985. Genetics of natural
resistance to herpes simplex virus type 1 latent infection of the peripheral nervous
system in mice. The Journal of General Virology 67:613-621.
Kim, H.S., Kwang, J., Yoon, I.J., Joo, H.S. and M.L. Frey. 1993. Enhanced
replication of porcine reproductive and respiratory syndrome (PRRS) virus in a
homogeneous subpopulation of MA-104 cell line. Archives of Virology 133:477483.
Kim, N.Y., Jung, W-W., Oh, Y-K., Chun, T., Park, H-Y., Lee, H-T., Han, IK., Yang, J.M., and Y.B. Kim. 2007. Natural protection from zoonosis by alphagal epitopes on virus particles in xenotransmission. Xenotransplantation 14:104111.
Klimstra, W.B., Ryman, K.D. and R.E. Johnston. 1998. Adaptation of Sindbis
virus to BHK cells selects for use of heparan sulfate as an attachment receptor.
Journal of Virology 72:7357-7366.
Koike, C., Friday, R., Fung, J.J., Starzl, T.E. and M. Trucco. 2001.
Comparison of the regulatory regions of the α1,3Galactosyltransferase gene
between murine and porcine species. Transplantation Proceedings 33:710-711.
Koike, C., Fung, J.J., Geller, D.A., Kannagi, R., Libert, T., Luppi, P.,
Nakashima, I., Profozich, J., Rudert, W., Sharma, S.B., Starz, T.E. and M.
Trucco. 2002. Molecular basis of evolutionary loss of the α1,3Galactosyltransferase gene in higher primates. The Journal of Biolocial Chemistry
12:10114-10120.
Koike, C., Uddin, M., Wildman, D.E., Gray, E.A., Truco, M., Starzl, T.E. and
M. Goodman. 2007. Functionally important glycosyltransferase gain and loss
during catarrhine primate emergence. Proceedings of the National Academy of
Sciences of the United States of America 104:559-564.





Krivan, H.C., Clark, G.F., Smith, D.F. and T.D. Wilkins. 1986. Cell surface
binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate
containing sequence Gal alpha 1-3Gal beta 1-4GlcNac. Infection and Immunity
53:573-581.
Kurkela, S., Rätti, O., Huhtamo, E., Uzcátegui, N.Y., Nuorti, J.P.,
Laakkonen, J., Manni, T., Helle, P., Vaheri, A. and O. Vapalahti. 2008.
Sindbis virus infection in resident birds, migratory birds and humans, Finland.
Emerging Infectious Diseases 14:41-47.
Lafferty, K.D. 2009. The ecology of climate change and infectious disease.
Ecology 90:888-900.
Larsen, R.D., Rajan, V.P., Ruff, M.M., Kukowska-Latolla, J., Cummings,
R.D. and J.B. Lowe. 1989. Isolation of a cDNA encoding a murine
UDPgalactose: β-D-galactosyl-1,3-N-acetyl-D-glucosamine α-1,3galactosyltransferase: expression cloning by gene transfer. Proceedings of the
National Academy of Sciences of the United States of America 86:8227-8231.
LaTemple, D.C. and U. Galili. 1998. Adult and neonatal anti-Gal response in
knock-out mice for α1,3galactosyltransferase. Xenotransplantation 5:191-196.
Lee, S., Cho, H-J, Park, J-J., Kim, Y-S., Hwang, S., Sun, R. and M.J. Song.
2007. The ORF49 protein of murine gammaherpesvirus 68 cooperates with RTA
in regulating virus replication. Journal of Virology 81:9870-9877.
Leroy, E.M., Rouquet, P., Formenty, P., Souquière, S., Kilbourne, A.,
Froment, J-M., Bermejo, M., Smit, S., Karesh, W., Swanepoel, R., Zaki, S.R.
and P.E. Rollin. 2004. Multiple Ebola virus transmission events and rapid
decline of central African wildlife. Science 303:387-390.
Lewis, J., Wesselingh, S.L., Griffin, D.E. and J.M. Hardwick. 1996.
Alphavirus-induced apoptosis in mouse brains correlates with neurovirulence.
Journal of Virology 70:1828-1835.
Lustig, S., Jackson, A.C., Hahn, C.S., Griffin, D.E., Strauss, E.G. and J.H.
Strauss. 1988. Molecular basis of Sindbis virus neurovirulence in mice. Journal
of Virology 62:2329-2336.
Manickan, E. and B.T. Rouse. 1995. Roles of different T-cell subsets in control
of herpes simplex virus infection determined by using T-cell-deficient mouse
models. Journal of Virology 69:8178-8179.
Maravelis, A. and A. Zelilidis. 2012. Paleoclimatology and Paleoecology across
the Eocene/Oligocene boundary, Thrace Basin, Northeast Aegean Sea, Greece.
Paleogeography, Paleoclimatology, Paleoecology 365-366:81-98.





Martin, M.J., Rayner, J.C., Gagneux, P., Barnwell, J.W. and A. Varki. 2005.
Evolution of human-chimpanzee differences in malaria susceptibility: relationship
to human genetic loss of N-glycolylneuramic acid. Proceedings of the National
Acadamy of Sciences of the United States of America 102:12819-12824.
McKnight, K.L., Simpson, D.A., Lin, S-C., Knott, T.A., Polo, J.M., Pence,
D.F., Johannsen, D.B., Heidner, H.W., Davis, N.L. and R.E. Johnston. 1996.
Deduced consensus sequence of Sindbis virus strain AR339: mutations contained
in laboratory strains which affect cell culture and in vivo phenotypes. Journal of
Virology 70:1981-1989.
McMorrow, I.M., Comrack, C.A., Nazarey, P.P. Sachs, D.H. and H.
DerSimonian. 1997. Relationship between ABO blood group and levels of
Gal[alpha],3galactose-reactive human Immunoglobulin 1. Transplantantion
64:546-549.
McNamee, E.E., Taylor, T.J. and D.M. Knipe. 2000. A dominant-negative
herpesvirus protein inhibits intranuclear targeting of viral proteins: effects on
DNA replication and late gene expression. Journal of Virology 74:10122-10131.
Messaoudi, I., Estep, R., Robinson, B. and S.W. Wong. 2011. Nonhuman
primate models of human immunology. Antioxidants & Redox Signaling 14:261273.
Michaud, F., Coulombe, F., Gaudreault, É, Kriz, J. and J. Gosselin. 2010.
Involvement of TLR2 in recognition of acute gammaherpesvirus-68 infection.
PLoS One. [e13742. doi:10.1371/journal.pone.0013742].
Milland, J., Christiansen, D., Lazarus, B.D., Taylor, S.G., Xing, P.X. and
M.S. Sandrin. 2006. The molecular basis for Galα(1,3)Gal expression in animals
with a deletion of the α1,3Galactosyltransferase gene. The Journal of
Immunology 176:2448-2454.
Mills, J.N., Gage, K.L. and A.S. Khan. 2010. Potential influence of climate
change on vector-borne and zoonotic disease: a review and proposed research
plan. Environmental Health Perspectives 118:1507
Mogensen, S.C., Tiesner, B. and H. Kerzel Andersen. 1974. Focal necrotic
hepatitis in mice as a biological marker for differentiation of Herpesvirus hominis
type 1 and type 2. Journal of General Virlogy 25: 151-155.
Nottle, MB., Beebe, L.F.s., Harrison, S.J., McIlfatrick, S.M., Ashman, R.J.,
O’Connell, P.J., Salvaris, E.J., Fisicaro, N., Pommey, S., Cowan, P.J. and
A.J.F. d’Apice. 2007. Production of homozygous α-1,3-galactosyltransferase
knockout pigs by breeding and somatic cell nuclear transfer. Xenotransplantation
14:339-344.





Olofsson, S. and T. Bergström. 2005. Glycoconjugate glycans as viral receptors.
Annals of Medicine 37:154-172.
Orlandi, P.A., Klotz, F.W. and J.D. Haynes. 1992. A malaria invasion receptor,
the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum
recognizes the terminal Neu5Ac(α2-3)Gal- sequences of Glycophorin A. The
Journal of Cell Biology 116:901-909.
Pearson, P.N., McMillan, I.K., Wade, B.S., Jones, T.D., Coxall, H.K., Bown,
P.R. and C.H. Lear. 2012. Extinction and environmental change across the
Eocene-Oligocene boundary in Tanzania. Geology 36:179-182.
Pedersen, A.B., Jones, K.E., Nunn, C.L. and S. Altizer. 2006. Infectious
diseases and extinction risk in wild mammals. Conservation Biology 21:12701279.
Perelman, P., Johnson, W.E., Roos, C., Seuánez, H.N., Horvath, J.E.,
Moreira, M.A.M., Kessing, B., Pontius, J., Roelke, M., Rumpler, Y.,
Schneider, M.P.C., Silva, A., O’Brien, S.J., and J. Pecon-Slattery. 2011. A
molecular phylogeny of living primates. PLoS Genetics
7:[doi:10.1371/journal.pgen.1001342].
Phelps, C.J., Koike, C., Vaught, T.D., Boone, J., Wells, K.D., Chen, S.H.,
Ball, S., Specht, S.M., Polejaeva, I.A., Monahon, J.A., Jobst, P.M., Sharma,
S.B., Lamborn, A.E., Garst, A.S., Moore, M., Demetris, A.J., Rudert, W.A.,
Bottion, R., Bertera, S., Trucco, M., Starzl, T.E., Dai, Y. and D.L. Ayares.
2003. Production of α1,3-Galactosyltransferase-deficient pigs. Science 299:411414.
Pingel, S., Rheinweiler, U., Kolb, V. and M. Duszenko. 1999. Purification and
characterization of an α-galactosyltransferase from Trypanosoma brucei.
Biochemical Journal 338:545-551.
Poste, G., Doll, J., Hart I.R. and I.J. Fidler. 1980. In vitro selection of murine
B16 melanoma variants with enhanced tissue-invasive properties. Cancer
Research 40:1636-1644.
Pothoulakis, C., LaMont, J.T., Eglow, R., Gao, N., Rubins, J.B., Theoharides,
T.C. and B.F. Dickey. 1991. Characterization of rabbit ileal receptors for
Clostridium difficile toxin A. Evidence for a receptor-couple G protein. 88:119125.
Prothero, D.R. 1994. The late Eocene-Oligocene extinctions. Annual Review of
Earth and Planatary Sciences 22:145-65.





Pozzi, L., Hodgson, J.A., Burrell, A.S. and T.R. Disotell. 2011. The stem
catarrhine Saadanius does not inform the timing of the origin of crown
caterrhines. Journal of Human Evolution 61:209-210.
Raaum, R.L., Sterner, K.N., Noviello, C.M., Stewart, C-B. and T.R. Disotell.
2005. Catarrhine primate divergence dates estimated from complete
mitochondrial genomes: concordance with fossil and nuclear DNA evidence.
Journal of Human Evolution 48:237-257.
Ramasamy, R. and R. Rajakaruna. 1997. Association of malaria with
inactivation of α1,3-galactosyltransferase in catarrhines. Biochimica et
Biophysica Acta (BBA) -Molecular Basis of Disease 1360:241-246.
Reiter, P. 2001. Climate change and mosquito-borne disease. Environmental
Health Perspectives 109:141-160.
Reitter, J.N. and R.C. Desrosiers. 1998. Identification of replication-competent
strains of simian immunodeficiency virus lacking multiple attachment sites for Nlinked carbohydrates in variable regions 1 and 2 of the surface envelope protein.
Journal of Virology 72:5399-5407.
Reinarz, A.B.G., Broome, M.G. and B.P. Sagik. 1971. Age-dependent
resistance of mice to Sindbis virus infection: Viral replication as a function of
host age. Infection and Immunity 3:268-273.
Renis, H.E., Eidson, E.E., Mathews, J. and J.E. Gray. 1976. Pathogenesis of
herpes simplex virus type 1 and 2 in mice after various routes of inoculation.
Infection and Immunity 14:571-578.
Repik, P.M., Strizki, J.M. and U. Galili. 1994. Differential host dependent
expression of α-galactosyl epitopes on viral glycoproteins: A study of Easter
equine encephalitis virus as a model. Journal of General Virology 75:1177-1181.
Rich, S.M., Leendertz, F.H., Xu, G., LeBreton, M., Djoko, C.F., Aminake,
M.N., Takang, E.E., Diffo, J.L.D., Pike, B.L., Rosenthal, B.M., Formenty, P.,
Boesch, C., Ayala, F.J. and N.D. Wolfe. 2009. The origin of malignant malaria.
Proceedings of the National Academy of the Sciene 106:14902-14907.
Rose, P.P., Hanna, S.L., Spiridigliozzi, A., Wannissorn, N., Beiting, D.P.,
Ross, S.R., Hardy, R.W., Bambina, S.A., Heise, M.T. and S. Cherry. 2011.
Natural resistance-associated macrophage protein is a cellular receptor for Sindbis
virus in both insect and mammalian hosts. Cell Host and Microbe 10:97-104.
Rosenberg, G.L., Wohlenberg, C., Nahmias, A.J., A.L. Notkins. 1972.
Differentiation of type 1 and type 2 herpes simplex virus by in vitro stimulation of
immune lymphocytes. The Journal of Immunology 109:413-414.





Rother, R.P., Fodor, W.L., Springhorn, J.P., Birks, C.W., Setter, E., Sandrin,
M.S., Squinto, S.P. and S.A. Rollins. 1995. A novel mechanism of retrovirus
inactivation in human serum mediated by anti-α-galactosyl natural antibody. The
Journal of Experimental Medicine 182:1345-1355.
Rother, R.P. and U. Galili. 1999. α-Gal epitopes on Viral Glycoproteins. In Subcellular biochesmistry. Alpha-gal and anti-gal: α1,3galactosyltransferase, α-gal
epitopes, and the natural anti-gal antibody, RP Rother and U Galili (Eds.). New
York, NY: Kluwer Academic/Plenum Publishers, pp. 143-172.
Russel, D.L., Dalrymple, J.M. and R.E. Johnston. 1989. Sindbis virus
mutations which coordinately affect glycoprotein processing, penetration and
virulence in mice. Journal of Virology 63:1619-1629.
Ryman, K.D., Klimstra, W.B., Nguyen, K.B., Biron, C.A. and R.E. Johnston.
2000. Alpha/Beta interferon protects adult mice from fatal Sindbis virus infection
and is an important determinant of cell and tissue tropism. Journal of Virology
74:3366-3378.
Sammels, L.M., Lindsay, M.D., Poidinger, M., Coelen, R.J. and J.S.
Mackenzie. 1999. Geographic distribution and evolution of Sindbis virus in
Australia. Journal of Virology 80:739-748.
Schneider-Schaulies, J. 2000. Cellular receptors for viruses: links to tropism and
pathogenesis. Journal of General Virology 81:1431-1429.
Seiffert, E.R. 2007. Evolution and extinction of Afro-Arabian primates near the
Eocene-Oligocene boundary. Folia Primatologica 78:314-327.
Shenk, T.E. and V. Stollar. 1973. Defective-interfering particles of Sindbis
virus: isolation and some chemical and biological properties. Virology 53:162173.
Shieh, M-T., WuDunn, D., Montgomery, R.I., Esko, J.D. and P.G. Spear.
1992. Cell surface receptors for herpes simplex virus are heparan sulfate
proteoglycans. The Journal of Cell Biology 116:1273-1281.
Shukla, D., Liu, J., Blaiklock, P., Shworak, N.W., Bai, X., Esko, J.D., Cohen,
G.H., Eisenberg, R.J., Rosenberg, R.D. and P.G. Spear. 1999. A novel role for
3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13-22.
Spear, P.G. and R. Longnecker. 2003. Herpesvirus entry: an update. Journal of
Virology 77:10179-10185.





Steiper, M.E., Young, N.M. and T.Y. Sukarna. 2004. Genomic data support the
hominoid slowdown and an early Oligocene estimate for the hominoidcercopithecoid divergence. Proceedings of the National Academy of Sciences of
the United States of America 101:17021-17026.
Steiper, M.E. and N.M. Young. 2008. Timing primate evolution: Lessons from
the discordance between molecular and paleontological estimates. Evolutionary
Anthropology 17:179-188.
Stewart, C-B. and T.R. Disotell. 1998. Primate evolution – in and out of Africa.
Current Biology 8:R582-R588.
Stiles, K.M. and M. Kielian. 2011. Alphavirus entry: NRAMP leads the way.
Cell Host & Microbe. 10:92-93. [Open Access doi:10.1016/j.chom.2011.07.008].
Strahan, K.M., Gu, F., Preece, A.F., Gustavsson, I., Andersson, L. and K.
Gustafsson. 1995. cDNA sequence and chromosome localization of pig
α1,3galactosyltrasnferase. Immunogenetics. 41:101-105.
Strauss, J.H. and E.G. Strauss. 1994. The Alphaviruses: Gene expression,
replication and evolution. Microbiological Reviews 58:491-562.
Sunil-Chandra, N.P., Efstathiou, S., Arno, J. and A.A. Nash. 1992. Virological
and pathological features of mice infected with murine gamma-herpes 68. The
Journal of General Virology 73:2347-2356.
Suzuki, Y., Ito, T., Suzuki, T., Holland Jr, R.E., Chambers, T.M., Kiso, M.,
Ishida, H. and Y. Kawaoka. 2000. Sialic acid species as a determinant of the
host range of influenza A viruses. Journal of Virology 74:11825-11831.
Takeuchi, Y., Liong, S-H., Bieniasz, P.D., Jäger, U., Porter, C.D., Friedmann,
T., McClure, M.O., and R.A. Weiss. 1997. Sensitization of Rhabdo-, Lenti-, and
Spumaviruses to human serum by galactosyl(α1,3)galactosylation. Journal of
Virology 71:6174-6178.
Tanemura, M., Maruyama, S. and U. Galili. 2000. Differential expression of αGal epitopes (Galα1,3Galβ1,4GlcNAc-R) on pig and mouse organs.
Transplantation 69:187-190.
Taylor, R.M., Hurlbut, H.S., Work, T.H., Kingston, J.R. and T.E.
Frothingham. 1955. Sindbis virus: a newly recognized arthropod-transmitted
virus. Tropical Medicine and Hygene 4:844-862.





Teneberg, S., Lönnroth, I., Torres López, J.F., Galili U., Ölwegård
Halvarsson, M., Ångström, J., and K-A. Karlsson. 1990. Molecular mimicry
in the recognition of glycosphingolipids by Galα3GalβGLcNAcβ-binding
Clostridium difficile toxin A, human natural anti α-galactosyl IgG and the
monoclonal antibody Gal-13: characterization of a bindin-active human
glycosphingolipid, non-identical with the animal receptor. Glycobiology 6:599609.
Thall, A. and U. Galili. 1990. Distribution of the Galα1,3Galβ1,4GlcNAc
residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and
immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay.
Biochemistry 29:3959-3965.
Thall, A.D., Malý, P. and J.B. Lowe. 1995. Oocyte Galα1,3Gal epitopes
implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not
required for fertilization in the mouse. The Journal of Biological Chemistry
270:21437-21440.
Van Blerkom, L.M.V. 2003. Role of viruses in human evolution. Yearbook of
Physical Anthropology 46:14-46.
Varki, A. 2010. Uniquely human evolution of sialic acid genetics and biology.
Proceedings of the National Academy of Sciences of the United States of America
107:8939-8946.
Varki, N.M. and A. Varki. 2007. Diversity in cell surface sialic acid
presentations: implications for biology and disease. Laboratory Investigation
87:851-857.
Vigerust, D.J. and V.L. Sheperd. 2007. Virus glycosylation: role in virulence
and immune interactions. Trends in Microbiology 15: 211-218.
Vines, A., Wells, K., Matrosovich, M., Castrucci, M.R., Ito, T. and Y.
Kawaoka. 1998. The role of influenza A virus haemagglutinin residues 226 and
228 in receptor specificity and host range restriction. Journal of Virology
72:7626-7631.
Wade, B.S., Houben, A.J.P., Quaijtaal, W., Schouten, S., Rosental, Y., Miller,
K.G., Katz, M.E., Wright, J.D. and H. Brinkhuis. 2012. Multiproxy record of
abrupt sea-surface cooling across the Eocene-Oligocene transition in the Gulf of
Mexico. Geology 40:159-162.
Wang, G. 2008. Sindbis virus interaction with cells. PhD. Dissertation, North
Carolina State University, -Raleigh, North Carolina.





Weis, W., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J. and D.C.
Wiley. 1988. Structure of the influenza virus haemagglutinin complexed with its
receptor, sialic acid. Nature 333:426-431.
Welsh, R.M., Cooper, N.R., Jensen, F.C. and M.B.A. Oldstone. 1975. Human
serum lyses RNA tumour viruses. Nature 257:612-614.
Welsh, R.M., Jensen, F.C., Cooper, N.R and M.B.A. Oldstone. 1976.
Inactivation and lysis of oncornaviruses by human serum. Virology 74:432-440.
Welsh, R.M. 1977. Host cell modification of lymphocytic choriomeningitis virus
and Newcastle disease virus altering viral inactivation by human complement.
Journal of Immunology 118:348-354.
Welsh, R.M., O’Donnell, C.L., Reed, D.J. and R.P. Rother. 1998. Evaluation
of the Galα1-3Gal epitope as a host modification factor eliciting natural humoral
immunity to enveloped viruses. Journal of Virology 72:4650-4656.
Whitbeck, J.C., Peng, C., Loud, H., Xu, R., Willis, S.H., Ponce de Leon, M.,
Peng, T., Nicola, A.V., Montgomery, R.I., Warner, M.S., Soulika, A.M.,
Spruce, L.A., Moore, W.T., Lambris, J.D., Spear, P.G., Cohen, G.H. and R.J.
Eisenberg. 1997. Glycoprotein D of herpes simplex virus (HSV) binds directly to
HVEM, a member of the tumor necrosis factor receptor superfamily and a
mediator of HSV entry. Journal of Virology. 71:6083-6093.
White, D.W., Keppel, C.R., Schneider, S.E., Reese, T.A., Coder, J., Payton,
J.E., Ley, T., Virgin, H.W. and T.A. Fehniger. 2012. Latent herpesvirus
infection arms NK cells. Immunobiology 115:4377-4383.
Williams, B.A., Kay, R.F. and E.C. Kirk. 2010. New perspective on anthropoid
origins. Proceedings of the National Academy of Sciences of the United States of
America 107:4797-4804.
WuDunn, D. and P.G. Spear. 1989. Initial interaction of herpes simplex virus
with cells is binding to heparan sulfate. Journal of Virology 63:52-58.
Wyatt, K.B., Campos, P.F., Gilbert, M.T.P., Kolokotronis, S-O., Hynes,
W.H., DeSalle, R., Daszak, P., MacPhee, R.D.E. and A.D. Greenwood. 2008.
Historical mammal extinction on Christmas Island (Indian Ocean) correlates with
introduced infectious disease. PloS ONE 3:e3602.
[doi:10.1371/journal.pone.0003602].





Zalmout, I.S., Sanders, W.J., MacLatchy, L.M., Gunnel, G.F., Al-Mufarreh,
Y.A., Ali, M.A., Nasser, A-A.H., Al-Masari, A.M., Al-Sobhi, S.A., Nadhra,
A.O., Matari, A.H., Wilson, J.A. and P.D. Gingerich. 2010. New Oligocene
primate from Saudi Arabia and the divergence of apes and Old World monkeys.
Nature 466:360-365.
Zhu, A., Leng, L., Monahan, C., Zhang, Z., Hurst, R., Lenny, L. and J.
Goldstein. 1996. Characterization of recombinant α-galactosidase for use in
seroconversion from blood group B to O of human erythrocytes. Archives of
Biochemistry and Biophysics 327:324-329.
Zhu, Y., Lau, A., Lau, J., Jia, Q., Karuppannan, A.K. and J. Kwang. 2007.
Enhanced replication of porcine circovirus type 2 (PCV2) in a homogeneous
subpopulation of PK15 cell line. Virology 369:423-430.





